



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 552 931 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
24.05.2000 Bulletin 2000/21

(51) Int. Cl.⁷: **C12Q 1/68**

(21) Application number: **93300377.4**

(22) Date of filing: **20.01.1993**

(54) **Hybridization assay using branched nucleic acid probes**

Hybridisierungsassay unter Verwendung von verzweigten Nukleinsäuresonden

Essai d'hybridation utilisant des sondes acides nucléiques ramifiées

(84) Designated Contracting States:
CH DE FR GB IT LI SE

(30) Priority: **22.01.1992 US 827021**

(43) Date of publication of application:
28.07.1993 Bulletin 1993/30

(73) Proprietor:
Gen-Probe Incorporated
San Diego, CA 92121 (US)

(72) Inventors:
• **Hogan, James John**
Coronado, California 92118 (US)
• **Arnold, Lyle John, Jr.**
Poway, California 92064 (US)
• **Nelson, Norman Charles**
San Diego, California 92111 (US)
• **Bezverkov, Robert**
Cardiff By The Sea, California 92007 (US)

(74) Representative:
Sexton, Jane Helen et al
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5LX (GB)

(56) References cited:
EP-A- 0 070 685 **EP-A- 0 268 133**
EP-A- 0 427 074 **EP-A- 0 450 594**
EP-A- 0 453 301 **WO-A-85/05642**
WO-A-89/02476 **WO-A-89/04876**
WO-A-90/03446 **WO-A-90/15884**
US-A- 4 820 630

• **NACHRICHTEN AUS CHEMIE TECHNIK UND**
LABORATORIUM vol. 37, no. 7/8, 1989,
WEINHEIM DE pages 692 - 702 B.S.RECKMANN

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 552 931 B1

Description

[0001] This invention concerns hybridization assays and nucleic acid probes for use in such assays.

5 Background of the Invention

[0002] Nucleic acid is formed from nucleotide bases, e.g., uracil (U) cytidine (C), adenine (A), thymine (T) and guanine (G), formed as a single-stranded linear molecule. Such a linear molecule can form a hybrid complex, or double-stranded molecule (also called a duplex), with another linear molecule by forming specific base pairs, e.g., between A and T, A and U, or G and C. Such paired molecules are called complementary molecules.

10 **[0003]** Nucleic acid hybridization is a method in which two single-stranded complementary molecules form a double-stranded molecule. This method is commonly used to detect the presence of one single-stranded molecule in a sample (the target nucleic acid) by use of a labelled probe formed of a complementary single-stranded molecule. For example, Muran et al., WO 87/04165, published July 16, 1987, describes a probe having a single-stranded region complementary to the nucleic acid to be detected, and a double-stranded region having a non-radioactive label. The general uses and design of nucleic acid probes are well known in the art, see e.g., Mifflin 35 Clin. Chem. 1819, 1989 and Matthews and Kricka, 169 Anal. Biochem. 1, 1988.

15 **[0004]** Published International Application No. WO 90/03446 describes use of nucleic acid probes having a region complementary to a target sequence and two arm regions capable of hybridizing to each other only when the probe is not hybridized to a target.

20 **[0005]** EP-A 0450494 discloses DNA hybridization assays employing an oligonucleotide probe which is capable of simultaneously hybridizing to a target sequence and interacting with further oligonucleotides via hybridization to a bridging oligonucleotide to provide a branched nucleic acid structure with detectable labels.

25 **[0006]** DNA hybridization assays are also known employing more than one probe sequence on different oligonucleotides to hybridize to the target. Thus, Nachrichten Aus Chemie Technik Und Laboratorium (1989) 37 (7/8) 692-702 and US-A-4820630 describes a number of DNA hybridization assays, including such an assay employing two probe sequences on separate oligonucleotides which when hybridized to the target are detectable by means of interactive labels.

30 **[0007]** Published International Application No. WO 93/06246, which was not published until after the filing date of the present application, but has priority dates preceding the priority date of the present-application, also discloses DNA hybridization assays employing two oligonucleotides with probe sequences capable of hybridizing to the target. In these assays, when the two probe sequences are hybridized to the target, arm regions of the probe sequences also hybridize to each other. Detection of hybridization is carried out after treating the sample to permit chain extension of one probe sequence using part of the arm region of the second probe sequence as a template. A PCR reaction may be carried out.

Summary of the Invention

40 **[0008]** The present invention also provides hybridization assays based upon the use of probe sequences which form a detectable structure only in the presence of a target nucleic acid. However, detection of hybridization does not depend upon probe DNA extension. At least two probe sequences (which may be on different molecules) must hybridize with the target nucleic acid. Thus, the probe ensures that little or no false positive results are observed. Such probes can be used to detect nucleic acids and also can be used as therapeutic agents. They allow novel detection methods to be practised, independent of the structure of the target nucleic acid. In addition, amplification of a label signal can be readily achieved, such that the probes allow extremely sensitive levels of detection of target nucleic acid.

45 **[0009]** Thus, in a first aspect, the invention features a method for detecting the presence or amount of a target nucleic acid in a sample comprising the steps of:

50 contacting one or more nucleic acid molecules with said sample under a predetermined environmental condition to allow hybridization of said molecules if said target nucleic acid is present; wherein said one or more nucleic acid molecules together comprise at least two separate target regions which hybridize with said target nucleic acid under said predetermined environmental condition, and at least two arm regions, wherein said arm regions, under said predetermined environmental condition, do not hybridize with said target nucleic acid, or with each other in the absence of said target nucleic acid, but in the presence of said target nucleic acid do hybridize with each other; and
55 detecting any hybridization of said arm regions as an indication of the presence or amount of said target nucleic acid, wherein said detecting is not dependent upon interaction of two labels, one label being present on each arm region, and said method does not involve detecting products resulting from primer extension of either of said at least two arm regions.

[0010] In preferred embodiments, the detecting step includes contacting the arm regions with a resolvase (by which term is meant an enzyme able to resolve a junction by junction-specific cleavage, e.g., a 4-way junction or a 3-way junction) and detecting cleavage of the one or more nucleic acid molecules by the resolvase, performing a DNA footprint analysis of the one or more nucleic acid molecules, observing the mobility of the one or more nucleic acid molecules within a gel matrix, detecting the binding of an intercalator to the one or more nucleic acid molecules, contacting the one or more nucleic acid molecules with S1 nuclease and detecting any cleavage of the one more nucleic acid molecules by the nuclease, contacting the one or more nucleic acid molecules with a restriction endonuclease and detecting cleavage of the one more nucleic acid molecules by the endonuclease, or determining the thermal stability of the one or more nucleic acid molecules.

[0011] In other preferred embodiments, the one or more nucleic acid molecules include an intercalating molecule or nucleic acid binding molecule, e.g., an acridinium ester, or other molecule which is susceptible to chemical modification by an acid or a base, or other modification, when that molecule forms part of a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule, and is not susceptible to such chemical cleavage when the molecule is present in the other of the single-stranded nucleic acid molecule or double-stranded nucleic acid molecule; and the detecting step includes contacting the one or more nucleic acid molecules with the chemical and determining the amount of chemical modification of the molecule; at least one of the one or more nucleic acid molecules has a target region having between eight and 30 (or 8-100) complementary bases in a region of 50 (or 1000) contiguous bases of the target nucleic acid; the arm regions form a duplex in the absence of target nucleic acid with a melting temperature (commonly referred to as T_m , which is measured as described below) 4°C lower than the hybridization temperature in the predetermined environmental condition, most preferably 7°C or even 10°C lower, and in the presence of target nucleic acid form a duplex having a T_m at least 4°C (or 7°C, or even 10°C) greater than the hybridization temperature in the predetermined environmental condition.

[0012] In yet other preferred embodiments, one nucleic acid molecule is provided and the nucleic acid molecule has a loop region connecting the at least two arm regions; the one or more nucleic acid molecules consist of two nucleic acid molecules each having a target region and an arm region; the one or more nucleic acid molecules consist of three nucleic acid molecules each having at least one arm region, and at least two of the nucleic acid molecules having a separate target region, wherein the three nucleic acid molecules hybridize with the target nucleic acid to form at least two separate hybridized or duplex arm regions; the one or more nucleic acid molecules consist of four nucleic acid molecules each having at least one arm region, and at least two of the nucleic acid molecules have separate target regions, wherein the four nucleic acid molecules and the target nucleic acid hybridize to form at least three separate duplexes between the arm regions.

[0013] In still other preferred embodiments, the target regions hybridize with the target nucleic acid, and the arm regions hybridize together to form an arm, such that a junction is formed at the base of the arm between the two separate target regions. The one or more nucleic acid molecules or the target nucleic acid may include nucleic acid adjacent the junction which does not form a duplex with the arm regions or the target regions or the target nucleic acid, and loops out from the junction. Alternatively, the target regions include along their length, or at the ends distant from the arm regions, nucleic acid which does not form a duplex with the target nucleic acid and therefore either loops from a duplex formed between the target nucleic acid and the target region, or extends as a single-stranded region from the end of the target region. In yet another alternative, the arm regions include nucleic acid which does not form a duplex with the other arm region and forms a loop extending from the arm region or extends as a single-stranded molecule from the end of the arm region distant from the target region. In one example, the target regions hybridize with the target nucleic acid, and the arm regions hybridize together to form an arm, and a junction is formed at the base of the arm between the two separate target regions. One or both arm regions further has a single-stranded region at the end furthest from the target region which fails to hybridize to the other arm region, and thus is available for duplex formation with another nucleic acid molecule to form a second arm. In this example, the one or more nucleic acid molecules may include a portion able to form a duplex with the single-stranded regions to form a second or third arm and a second junction between the arms.

[0014] In related preferred embodiments, the at least two arm regions form an arm when hybridized with the target nucleic acid, and this arm includes a biologically or chemically active site, e.g. a restriction endonuclease site, a promoter for an RNA polymerase, which can be transcribed to form a plurality of RNA transcripts, a DNA-RNA duplex susceptible to cleavage by RNaseH or a chemical active to cleave adjacent duplex nucleic acid, e.g., $Fe \cdot$ EDTA.

[0015] In addition, an arm region or target region may include a single-stranded region which is able to loop over a duplex region to form triple-stranded nucleic acid. Such triple-stranded structures are well known in the art and can be readily designed as part of the present invention. Such a single-stranded nucleic acid may also be provided separate from the rest of the nucleic acid molecules, if desired, and can be labelled by standard methodology. Alternatively, it may form part of an arm or even target region. Detection of triple stranded nucleic acid is readily performed by methods known in the art.

[0016] The method may also include the step of contacting the one or more nucleic acid molecules and the target

nucleic acid with other nucleic acid molecules able to hybridize with the arm regions, or single-stranded regions extending from these arm regions, to form one or more duplex regions or arms, and these other nucleic acid molecules are then able to further hybridize among themselves to form a plurality of arms or arm regions.

[0017] Thus, the above probes can be incubated under suitable hybridization conditions with a sample suspected of containing the target nucleic acid, and detection of hybridization of the complementary arm regions used as an indication of the presence of target nucleic acid. Generally, the probe is formed from two or more separate nucleic acid molecules, e.g., strands of lengths between 20 and 50 bases; and the presence of hybridization is monitored by detection of an acridinium ester within the strands.

[0018] In another related aspect, the invention features a method for creating a biologically or chemically significant site which may be distant from the target nucleic acid yet is formed only in the presence of the target nucleic acid. This site is a segment of nucleic acid which is relatively inert in relation to a specific chemical or biochemical activity when it is in the single-stranded form, but becomes active in relation to specific chemical or biochemical activity when it is hybridized with its complementary strand, or vice versa. Examples of chemical or biochemical activity include, but are not limited to, a site susceptible to double-strand specific chemical cleavage (e.g., using an Iron-EDTA complex, or providing phenanthroline to duplex nucleic acid to make the duplex susceptible to copper cleavage), restriction endonuclease digestion, RNase H digestion (one strand of the duplex is RNA and one strand is DNA), or a site which can be acted upon by a T7 RNA polymerase. Other examples include sites which are digested when in the form of single-stranded nucleic acid (with S1 nuclease) but are protected from such digestion when in a double-stranded form. The nucleic acid hybridization probe having this site is designed as described above, except that it includes such a site, or such a site is created when the probe is hybridized with a complementary arm region. The probe is thus incubated with target nucleic acid to form a branched nucleic acid structure, as well as the desired site. Further chemistry or biochemistry is then performed as desired. This can be used, e.g., as a mode of detection, a mode of amplification, or a mode of target-mediated cleavage of nucleic acid.

[0019] In yet another related aspect, the invention features a method for mediating a biological activity within a target cell by hybridizing a probe, similar to those discussed above, to a specific target site. As described above, a probe is incubated with target nucleic acid to form a branched nucleic acid structure, including a duplex region formed between complementary arm regions. Examples of target nucleic acid in this method include essential sequences within the genome of a pathogenic organism, essential mRNA sequences produced by a pathogenic organism, and essential sequences within cancer cells. (By essential is meant that the viability of the organism or cell is reduced by at least 30%, as measured by techniques well known in the art, when such a sequence is deleted.) The duplex region formed between complementary arm regions of the probe is designed as a specific recognition site for one of a variety of therapeutic approaches, including a sequence-specific antibody recognition site (a specifically bound antibody will mediate therapy through any of a variety of well known mechanisms, e.g., a cell toxin linked to the antibody will kill the cell), and a sequence specific protein/enzyme binding (therapy is mediated by enzymatic cleavage, blocking of transcription, blocking of translation, and the like). Furthermore, the junction between nucleic acid strands can serve as the recognition site for such antibodies or proteins.

[0020] Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Description of the Preferred Embodiments

[0021] The drawings will first briefly be described.

Drawings

[0022]

FIGS. 1A-1F, 4A-4B, 6A-6H, 9A-9F, and 11A-11F are general diagrammatic representation of probes of this invention (the short lines between probes in each of the figures represent hydrogen bonding between the probes, and are not representative of actual number of bases or hydrogen bonds);

FIGS. 2A-2E and 3A-3B, 5A-5G, 7 and 8, 10, and 12A-12C are specific examples of the probe shown respectively in FIGS. 1A, 4A, 6A, 9F, and 11E;

FIGS. 13 and 14 are specific examples of mismatched probes;

FIGS. 15A-15D are diagrammatic representations of various detection systems useful in the invention;

FIG. 16 is a specific example of probes detectable by restriction endonuclease treatment;

FIG. 17 is an autoradiogram of a test with the probe shown in FIG. 16;

FIGS. 19A and 19B, and 20A-20C are diagrammatic representations of target-independent probe amplification systems;

FIG. 21 is a diagrammatic representation of three probes producing a 4-way junction; and

FIGS. 22A-22I are diagrammatic representations of various embodiments of the probes shown in FIG. 21.

Probes

[0023] Referring to FIGS. 1A and 1B, there is shown one example of a probe of this invention demonstrating the general structure of each probe of this invention. The probe shown is formed from two separate strands 10, 12 each of which possess a target-specific region 14, 16 able to hybridize under hybridizing conditions to a target nucleic acid 15. Each strand also possesses an arm region 18, 20 which hybridize together to form an arm 22 generally only in the presence of the target nucleic acid. When an arm is formed so also is a junction 21 between the arm and hybridized target regions. Arm regions and target specific regions can be designed so that hybridisation of the target specific regions to target nucleic acid is observed under hybridization conditions only when both strands are present in the hybridization mixture, and both are hybridized to target nucleic acid and to each other at their arm regions.

[0024] Thus, as generally discussed above, nucleic acid hybridization probes of this invention form branched nucleic acid structures (*i.e.*, structures having at least one arm extending from a target nucleic acid and not directly hybridized with the target nucleic acid) upon interaction with and hybridization to a target nucleic acid. The probes are designed so that formation of this branched structure is target-dependent. Therefore, detection of branch formation is a measure of the presence and the amount (if detection is quantitative) of target nucleic acid in a sample. More than one branch can be formed, but only one branch must be formed in a target-dependent manner. The probe can be a single nucleic acid strand or can be multiple strands. Furthermore, the strand (or strands) can be DNA, modified DNA, RNA, modified RNA, or various combinations thereof. By "modified DNA or RNA" is meant any nucleic acid structure differing from naturally occurring DNA or RNA molecules, *e.g.*, DNA or RNA, containing modified bases (*e.g.*, methyl cytosine, or inosine), or modified internucleotide linkages (*e.g.*, phosphorothioate, or methyl phosphonate). The probe must have at least two separate regions that hybridize specifically with the target nucleic acid, and at least two arm regions (*i.e.*, regions that do not hybridize with the target) that are complementary to one another and form a stable duplex only in the presence of target. Since these complementary arm regions hybridize only in the presence of target nucleic acid, detection of this duplex region is the preferred method to assay for the presence of the target nucleic acid.

[0025] There are numerous methods for detecting hybridization of branched nucleic acid probes with target. Examples of detection of branched nucleic acids include use of junction specific cleavage with a resolvase enzyme (*e.g.*, where cleavage of a labelled probe strand is detected), DNase footprinting, gel retardation assays, and binding of a labeled, junction specific intercalating compound (where the target is captured and the presence of label detected). While purified 4-way junction cleaving resolvases are known in the art, 3-way junction cleaving enzymes and other junction specific enzymes can be readily purified by art known methods, for example, by purifying enzymes biochemically which have an activity which cleaves a desired 3-way junction. Examples of detection of the duplex formed between complementary arm regions include DNase footprinting, S1 nuclease digestion (an arm region is labelled; if the arms form a duplex, they will not be digested with nuclease S1; if the arms do not form a duplex, they will be digested with nuclease S1), restriction endonuclease cleavage of a site created by duplex formation between complementary arm regions, capture of target nucleic acid followed by analysis of the thermal stabilities of the associated duplex(es) (using a labelled probe strand(s); the complete branched nucleic acid structure will have a higher thermal stability than any partial formation; if no formation has occurred, a different signal will be associated with the captured target nucleic acid compared to when a branch is formed).

[0026] The preferred method of detection is the use of the Hybridization Protection Assay (HPA) described by Arnold et al., 35 *Clin. Chem.* 1588, 1989. This method utilizes a chemiluminescent acridinium ester (AE) label covalently attached to a synthetic oligonucleotide probe. The assay format is completely homogeneous (*i.e.*, requires no physical separation steps) and is based on chemical hydrolysis of the ester bond of the AE molecule, cleavage of which renders the AE permanently non-chemiluminescent. Conditions have been developed where the hydrolysis of this ester bond is rapid for unhybridized AE-labeled probe (AE-probe) but slow for hybridized AE-probe. Therefore, after hybridization of the AE-probe with its complementary nucleic acid (under conditions that do not promote ester hydrolysis), the reaction conditions are adjusted so that the chemiluminescence associated with unhybridized AE-probe is rapidly reduced to low levels, while the chemiluminescence associated with hybridized AE-probe is minimally affected. Following this differential hydrolysis process, any remaining chemiluminescence is a direct measure of the amount of duplex formed. This assay method is used in the present invention by attaching one or more AE labels to one or more of the nucleic acid strands of the probe and assaying for duplex formation using the differential hydrolysis procedure described above.

Two Component Probes

[0027] One configuration of branched nucleic acid probe used for the detection of target nucleic acids is shown

schematically in FIGS. 1A and 1B. In this configuration the probe consists of two separate nucleic acid strands; these strands are preferably synthetic oligonucleotides. Each strand possesses a probe region which hybridizes with the target nucleic acid and an arm region. The two arm regions are complementary to one another (by which is meant not that they are necessarily perfectly complementary, since they may possess portions that are not complementary to each other at all, but that under hybridizing conditions a stable duplex is formed). These arm regions are designed such that the melting temperature, or T_m , of the associated duplex in the absence of target is less than the operating temperature of the assay, preferably 4°C less (more preferably 7°C or 10°C) than the operating temperature, so that little or no hybridization of the arm regions occurs in the absence of target nucleic acid. The T_m is defined as the temperature at which 50% of a given nucleic acid duplex has melted (*i.e.*, has become single-stranded). The T_m is dependent on environmental conditions such as the cation concentration of the solution. The desired T_m is typically achieved by manipulation of the length and nucleotide base composition of the complementary regions. Other methods can also be utilized to adjust duplex T_m , including but not limited to incorporation of mismatches, replacement of some or all of the guanosine residues with inosine, and modifying the phosphate backbone, *e.g.*, with phosphorothioate internucleotide linkages. When utilizing the HPA format at 60°C, the preferred length of exactly complementary, unmodified arm regions is approximately 8 to 20 contiguous bases (dependent on base composition and sequence). Other environmental conditions would potentially lead to a different size range; this is easily determined empirically.

[0028] Upon contacting the probe with a solution containing the target nucleic acid, the probe regions of the two strands will hybridize to their respective target regions, which are typically adjacent to one another, as shown in FIG. 1 (they do not have to be immediately adjacent, *see infra*). When this occurs, the arm regions of the two probe strands are constrained to be in close proximity to one another, thus increasing the stability of the associated duplex. The arm regions are designed such that the T_m of the duplex formed in the presence of target is approximately equal to or above the operating temperature of the assay, preferably 4°C above (more preferably 7°C or 10°C) the operating temperature such that the arms will form a duplex. As indicated above, when utilizing the HPA format at 60°C, the preferred length of the arms is approximately 8 to 20 contiguous complementary bases (dependent on base composition and sequence).

[0029] The probe regions of the two separate strands can be designed in a variety of manners. For example, these regions can be designed similarly to the arm regions in that the T_m of either region alone (*i.e.*, one probe strand plus the target strand) is below the operating temperature, but is above the operating temperature when both probe strands and the target strand are present and the arm regions are hybridized. They can also be designed such that the T_m 's of the probe regions are both above the operating temperature, or they can be designed such that one T_m is above and one T_m is below the operating temperature. Whatever design is chosen, the requirement that the arm regions form a stable duplex only in the presence of target must be met. The probe regions are preferably between 8 and 50 nucleotides in length, more preferably between 8 and 30 nucleotides in length. These regions can be longer, but most applications do not require this additional length, and synthesis of these longer oligomers is more costly and time consuming than the shorter oligomers.

[0030] One or both probe sequences is chosen to react with the desired target nucleic acid(s) and preferably to not react with any undesired target nucleic acid(s) (*i.e.*, cross-react). If one probe region hybridizes with an undesired target but the other probe region does not, the assay will still function properly since both probe segments have to hybridize in order for the arm regions to hybridize.

[0031] When utilizing the HPA format, the AE label is typically placed in the arm region of the probe. In the absence of target, this region will be single-stranded and the AE will be susceptible to rapid ester hydrolysis. In the presence of target, this region will be double-stranded and the AE will be protected from ester hydrolysis. An AE label can be placed in one strand, the other strand, or both strands (thereby leading to an increase in signal and assay sensitivity). Multiple labels can be placed in each strand, further improving assay sensitivity. The AE label can also be placed in one or the other (or both) of the probe regions. Multiple labels could also be used in this configuration. Furthermore, AE could be utilized in any combination of the placements just described.

[0032] To detect a target nucleic acid in a sample using the branched nucleic acid probe described above in the HPA format, the following general procedure is used: 1) add the branched nucleic acid probe to the sample, 2) incubate to allow annealing of the appropriate regions to occur, 3) add a reagent to effect differential hydrolysis of the AE label(s), and 4) detect any remaining chemiluminescence as an indication of the presence or amount of any target nucleic acid present. The annealing conditions can be varied depending on the exact application, the design of the probe, the nature of the target nucleic acid and the composition of the sample in which the target is contained. The conditions must be chosen, however, to fulfill the T_m requirements stated above. For the HPA format, the incubation temperature is preferably between 5 and 70°C, more preferably between 30 and 65°C; the pH of the annealing step is preferably between 4.5 and 8.5, and most preferably between 4.5 and 5.5 (greater stability of the AE during the annealing step is achieved in the lower pH range; however, methods exist to stabilize the AE in the higher pH range, as described by Hammond et al., 6 *J. Biolum. and Chemilum.* 35, 1991). The concentration of the monovalent salt counterion is preferably between 50 and 1000mM, more preferably between 200 and 800mM; it is preferred to include detergent in the annealing step

(this prevents the AE from aggregating and from sticking to the walls of the tube, and the pipet tips), preferably at concentrations between 0.1 and 10% (w/v), and more preferably between 1 and 10%. One skilled in the art will recognize that alternate annealing conditions that lead to the desired hybridization characteristics may also be used in this invention.

[0033] Although a specific example is provided below, this is not limiting in the invention. Those of ordinary skill in the art will recognize that many variations are possible, examples of which are provided in FIGS. 1C-1F, where various loops (labelled L) are shown in an arm, target nucleic acid or at a junction, and where single-stranded nucleic acid (labelled S) may also be present (e.g., for later duplex function with more probes as described below).

Example 1

[0034] A specific example of the general configuration shown in FIG. 1 is shown in FIG. 2A. The target strand is a synthetic DNA oligomer 43 bases in length with a sequence corresponding to a region of the 23S ribosomal RNA (rRNA) subunit of *Mycobacterium tuberculosis*. The 2 strands of the branched nucleic acid probe form a 3-way junction with the target strand as shown in FIG. 2A. A single AE is covalently tethered to strand 1 between a T and an A residue as shown.

[0035] Oligonucleotides were synthesized using standard phosphoramidite solid-phase chemistry (Caruthers et al., 154 *In Methods Enzymol.* 287, 1987) on a Biosearch Model 8750 or ABI 380A DNA Synthesizer and purified using standard polyacrylamide gel electrophoresis. Strand 1 was AE-labeled as previously described by Arnold and Nelson, PCT Publication No. WO 89/02896, published April 6, 1989.

[0036] The following annealing reactions were carried out for 1 hour at 60°C in 30µl of 0.1M lithium succinate buffer, pH 5.2, 2mM EDTA, 2mM EGTA, and 10% (w/v) lithium lauryl sulfate: Hybrid - 0.5 pmol of target strand, 0.05 pmol of probe strand 1 (the AE-labeled strand), and 2.5 pmol of probe strand 2. Control 1 - 0.05 pmol of probe strand 1, and 2.5 pmol of probe strand 2. Control 2 - 0.05 pmol of probe strand 1. Reagent Blank - No target or probe.

[0037] To demonstrate that the arm regions were hybridizing only in the presence of target, the half-life of AE hydrolysis for each of the reactions above were measured using the protocol described previously (Arnold et al., 35 *Clin Chem.* 1588, 1989). The following results were obtained:

Hybrid:	11.5 minutes
Control 1:	0.54 minutes
Control 2:	0.51 minutes

[0038] These data reveal that the AE is not protected from ester hydrolysis in the absence of target (compare Control 1 with Control 2), but is protected from hydrolysis in the presence of target (Hybrid), thus demonstrating the hybridization of the arm regions only in the presence of target nucleic acid.

[0039] This system was further evaluated by measuring the T_m's of the various configurations represented schematically in FIG. 2B. The T_m's were measured according to the following protocol:

- After annealing as described above, samples to be analyzed were diluted in 0.1M lithium succinate buffer, pH 5.2, 2mM EDTA, 2mM EGTA, 10% (w/v) lithium lauryl sulfate to approximately 100,000 relative light units (RLU; this is the unit of chemiluminescence used in these protocols; see Arnold et al., 35 *Clin Chem.* 1588, 1989) per 100µl.
- Separate 100µl aliquots were pipetted into 12 X 75mm assay tubes. Each sample to be analyzed was incubated for 7 minutes at each of the following temperatures - 40, 43, 46, 49, 52, 55, 58, and 62°C for oligomers with T_m's of 56°C and below; and 50, 53, 56, 59, 62, 65, 68, and 71°C for oligomers with T_m's above 56°C. After incubation, each tube was placed in an ice bath.
- After all incubations were complete, all tubes were removed from the ice bath and to each 300µl of 0.15M sodium tetraborate buffer, pH 7.6, 5% (v/v) Triton X-100 added, and vortex mixed. All tubes were incubated at 40°C for 20 minutes for oligomers with T_m's of 56°C and below, and at 50°C for 15 minutes for oligomers with T_m's above 56°C. The tubes were placed on ice for 30 seconds, and then at room temperature (20-25°C).
- Chemiluminescence was measured in a luminometer (LEADER I, Gen-Probe, CA) by the automatic injection of 200µl of 0.1% H₂O₂, 1N NaOH, followed by measurement of signal for 5 seconds. The tubes were blotted with a moist tissue or paper towel before measuring the chemiluminescence.
- The Control value was subtracted from each corresponding Hybrid value, and the resulting data plotted as chemiluminescence versus temperature. The T_m was determined graphically as the temperature at which 50% of

the maximum chemiluminescence is lost.

[0040] The temperature range and the exact temperature intervals used can vary with the exact characteristics of the AE-oligomer being characterized.

[0041] The following T_m's were obtained:

Structure 1	(FIG. 2B) T _m = 62°C
Structure 2	(FIG. 2C) T _m = 50°C

[0042] These data demonstrate that the duplex associated with the arm regions has a T_m well below 60°C (the operating temperature used above in the hydrolysis rate determination) in the absence of target, and a T_m above 60°C in the presence of target.

[0043] The system was further characterized by measuring T_m's of the various structures depicted in FIG. 2B-2E in 8mM lithium succinate buffer, pH 5.5, 100mM NaCl, 10mM MgCl₂, and 10mM Tris-HCl (this reagent replaces the diluting reagent in step 1 of the above protocol). The following T_m's were obtained:

Structure 1	(FIG 2B) T _m = 59°C
Structure 2	(FIG 2C) T _m = 47°C
Structure 3	(FIG 2D) T _m = 47°C
Structure 4	(FIG 2E) T _m = 45°C

[0044] For this particular design, not only is the T_m of the arm region much lower in the absence of target than in the presence of target, but the duplex regions forced between the target and the probe regions are less stable in the absence of the complete arm duplex (see FIG. 2) than in the presence of the complete arm duplex. This demonstrates that the branched nucleic acids of this invention can be used to manipulate the T_m of a nucleic acid duplex.

[0045] Other possible configurations for acridinium ester label locations, or use of a restriction enzyme (BstIII) for duplex detection are shown in FIGS. 2B-2E.

Example 2

[0046] Another example of the general structure shown in FIG. 1 is shown in FIGS. 3A and 3B. In this design ribosomal RNA (rRNA) from Neisseria gonorrhoeae is the target nucleic acid. All oligomers were synthesized and AE-labeled as described in Example 1 above. Two basic designs were evaluated, with junctions at slightly different locations within a given region of the rRNA (99/135 FIG. 3B and 132/146 FIG. 3A designs). A variety of linker-arm placements were evaluated, as indicated below. Furthermore, the exactly complementary target nucleic acid (N. gonorrhoeae) as well as a potentially cross-reacting target nucleic acid with 2 mismatches (N. meningitidis) were evaluated.

[0047] Hybridization characteristics of the different regions were evaluated using differential hydrolysis and T_m analyses as described in Example 1 with the following specific conditions:

	Target nucleic acid (RNA)		Oligo 99		Oligo 135		Oligo 146	
Sample	Type	Amount	Label	Amount	Label	Amount	Label	Amount
1	N.gon.	0.6 pmol	AE	0.1 pmol	none	2 pmol	none	2 pmol
2	N.gon.	0.6 pmol	none	2 pmol	AE(1)	0.1 pmol	none	2 pmol
3	N.gon.	0.6 pmol	AE	0.1 pmol	AE(1)	0.1 pmol	none	2 pmol
4	N.gon.	0.6 pmol	none	2 pmol	AE(2)	0.1 pmol	none	2 pmol
5	N.men.	0.6 pmol	AE	0.1 pmol	none	2 pmol	none	2 pmol
6	N.men.	0.6 pmol	none	2 pmol	AE(1)	0.1 pmol	none	2 pmol
7	N.men.	0.6 pmol	AE	0.1 pmol	AE(1)	0.1 pmol	none	2 pmol
8	N.gon.	0.6 pmol	none	2 pmol	AE(2)	0.1 pmol	none	2 pmol
			Oligo 132		Oligo 146		Oligo 100	
9	N.gon.	0.6 pmol	AE	0.1 pmol	none	2 pmol	none	2 pmol
10	N.gon.	0.6 pmol	none	2 pmol	AE	0.1 pmol	none	2 pmol
11	N.gon.	0.6 pmol	AE	0.1 pmol	AE	0.1 pmol	none	2 pmol
12	N.men.	0.6 pmol	AE	0.1 pmol	none	2 pmol	none	2 pmol
13	N.men.	0.6 pmol	none	2 pmol	AE(1)	0.1 pmol	none	2 pmol
14	N.men.	0.6 pmol	AE	0.1 pmol	AE(1)	0.1 pmol	none	2 pmol

[0048] Hybridizations with *N. gonorrhoeae* were performed at 60°C; hybridizations with *N. meningitidis* were performed at 45 or 50°C; controls contained all the components except target; linear oligonucleotides 100 and 146 are "helper" probes that open the secondary structure of the rRNA, and are not related to the branched nucleic acid probes of this invention. The following results were obtained:

Sample	Target	Tm(°C)	Hydrolysis Half-life(min)		
			Hybrid	Control	D.H. Ratio
1	N.gon	68.2	14.3	0.48	29.8
2	N.gon	70.0	6.5	0.51	12.7
3	N.gon	68.0	8.2	0.50	16.4
4	N.gon	68.5	18.8	0.47	40.0
9	N.gon	70.0	12.8	0.49	26.1
10	N.gon	72.0	8.0	0.43	18.6
11	N.gon	67.5	8.6	0.43	20.0
5	N.men	59.0			
6	N.men	59.0			
7	N.men	54.5			
8	N.men	56.0			
12	N.men	58.5			
13	N.men	61.0			

(continued)

Sample	Target	T _m (°C)	Hydrolysis Half-life(min)		
			Hybrid	Control	D.H. Ratio
14	N.men	57.0			
DH ratio is the ratio of half-life for hybrid and control. <u>Neisseria meningitidis</u> DH ratios were near unity (data not shown). Thus, no hybridization was observed.					

[0049] The DH ratios for the N. gonorrhoeae target clearly demonstrate that the arm regions form a stable duplex only in the presence of an RNA nucleic acid target. These two designs each have a strand with a long probe region and a strand with a short probe region, thus demonstrating the flexibility of this design parameter. Furthermore, the data demonstrate that several different AE placements yield similar results, including 2 AE's per probe (one per each strand; samples 3 and 11). Some AE placements yield higher DH ratios than other placements, but all show protection only in the presence of target. The T_m data for the N. gonorrhoeae target show that all structures tested yield T_m's well above the operating temperature (60°C in this case).

[0050] The data generated with the N. meningitidis target demonstrate that the system can be tuned to not significantly cross-react with a closely related target nucleic acid, thus improving its utility as an assay. The differences in T_m for each structure between N. gonorrhoeae and N. meningitidis range between 9.2 and 13.5°C.

[0051] The 99/135 system was also evaluated for its ability to detect decreasing amounts of target nucleic acid (N. gonorrhoeae); cross-reaction with 10⁻¹ µg (63fmol) of N. meningitidis was also tested. The assay format was as follows: Target and probe were annealed in 100µl of 0.1M lithium succinate buffer, pH 5.2, 2mM EDTA, 2mM EGTA, and 10% (w/v) lithium lauryl sulfate for 60 min at 60°C. 300µl of 0.15M sodium borate buffer, pH 7.6, containing 5% Triton X-100 detergent were added, vortexed and incubated at 60°C for 10 minutes. Chemiluminescence was measured in a luminometer (LEADER I, Gen-Probe, CA) by the automatic injection of 200µl of 0.4N HNO₃, 0.1% H₂O₂, and then 200µl of 1N NaOH, followed by measurement of signal for 5 seconds.

[0052] In this example, the following probe mixtures were used: Probe mix 1 - 0.1pmol of AE-labeled oligo 99, 0.5pmol of oligo 135, and 2 pmol of oligo 146; Probe mix 2 - 0.1pmol of AE-labeled oligo 135, 0.5pmol of oligo 99, and 2 pmol of oligo 146; Probe mix 3 - 0.1pmol of AE-labeled oligo 99, 0.1pmol of AE-labeled oligo 135, and 2 pmol of oligo 146. The amounts of target assayed and the results are indicated below:

[N.gon.] (µg)	Probe Mix		
	1	2	3
5 X 10 ⁻²	370,848	188,161	475,161
10 ⁻²	66,398	37,016	112,844
10 ⁻³	9,242	4,730	14,249
[N.men.] (µg)			
10 ⁻¹	2,358	5,363	2,362

[0053] These data demonstrate that the designs shown here are useful in detecting small amounts of nucleic acid in a full assay format. Furthermore, label amplification is demonstrated in probe mix 3, which contains 2 AE-labeled strands instead of 1 (as in probe mixes 1 and 2). Cross-reaction with the very closely related N. meningitidis RNA was minimal for probe mixes 1 and 3; the slight cross-reaction seen in probe mix 2 is approximately 100-fold lower than the positive signal, and was reduced to minimal levels by slightly increasing the operating temperature of the assay.

One Component Probes

[0054] Another configuration of branched nucleic acid probe used for the detection of target nucleic acids is shown schematically in FIGS. 4A and 4B. In this configuration the probe consists of a single nucleic acid strand. The desired characteristics are the same as those described for the design shown in FIG. 1, but now the 2 strands of the probe are connected and therefore become 1 strand. A segment 24 connecting the two halves of the probe can be nucleotide or

non-nucleotide in nature, and should be of a length that yields the desired probe characteristics described above. When utilizing the HPA format at 60°C, the preferred length of the complementary, unmodified arms 25, 27 in this configuration is somewhat shorter than described for the design shown in FIG. 1 due to the intra-molecular nature of the interaction. Therefore, the preferred arm length is approximately 4 to 16 bases. As mentioned above, other environmental conditions, would potentially lead to a different size range; this is easily determined experimentally by standard procedures.

Example 3

[0055] An example of the general structure shown in FIG. 4 is shown in FIG. 5A. The target strand is a synthetic DNA oligomer 43 bases in length with a sequence corresponding to a region of the 23S rRNA subunit of *Mycobacterium tuberculosis*. All oligomers were synthesized and AE-labeled as described in Example 1 above. The branched nucleic acid probe forms a 3-way junction with the target strand as shown in FIG. 5A. A single AE is covalently tethered to the probe between a T and an G residue as shown. An AE was also placed in the target strand at one of the two locations indicated in certain analyses as described below.

[0056] Hybridization characteristics of the structures depicted in FIGS. 5B-5G were evaluated using DH and T_m analysis protocols described in Example 1; the amounts of each component used in the respective annealing reactions are listed in FIGS. 5B-5G. The following results were obtained:

Sample	Hydrolysis Half-life(min)		
	Hybrid	Control	D.H. Ratio
1	5.8	1.2	4.8
2	10.2	0.32	31.9
3	8.1	0.56	14.5

[0057] These data demonstrate that the duplex formed between arm regions is more stable in the presence of target than the absence of target, as revealed by the increased AE stability. The relative difference in stability is large enough to be used to clearly detect the presence of target nucleic acid, but is not as great as that seen in either Example 1 or 2. Comparing the control hydrolysis rates of samples 1, 2 and 3, it is clear that the arms are interacting slightly under the operating conditions of this experiment. This interaction can be essentially eliminated by optimizing the operating conditions (e.g., higher operating temperature, inosine residues included in the arm regions, or phosphorothioate linkages included in the arm regions). This improves discrimination between the target present and target absent cases.

[0058] Other configurations of branched nucleic acid probes used for the detection of target nucleic acids are shown schematically in FIGS. 6A-6H. In these configurations the probe consists of three or more nucleic acid strands which form one or more nucleic acid junctions with the target nucleic acid. As above, such structures can be designed within a single nucleic acid molecule. Virtually any combination of junctions is possible as long as the arm regions form a stable duplex only in the presence of target (the possibility of some of the arm regions forming a stable duplex even in the absence of target will be discussed later). The guidelines for designing such a system are essentially the same as those described above for the configuration shown in FIG. 1. In the case of four way junctions (or even higher order junctions), some of the strands of the probe will contain only arm regions and no target specific regions. Since the sequence(s) of the strand(s) that contains only arm regions is independent of target sequence, this sequence(s) can be used in combination with a variety of specific probe strands for detection of a variety of target sites. This "universal detection" approach has several advantages, including the ability to use very few (or even only one) AE-labeled universal detection oligomer for the detection of all target sequences (this greatly minimizes design and synthesis time, therefore minimizing cost) and freedom to select the sequence that yields optimal differential hydrolysis, completely independent of target sequence.

[0059] As described above, AE can be placed in some or all of the arm regions as well as some or all of the probe regions. One advantage of this configuration is that there are many sites for AE, thus greatly increasing the label amplification potential of the assay. In one particular usage, the sequence around the AE site can be the same for each arm region, leading to uniformity of AE hydrolysis characteristics (AE hydrolysis rates are sequence-dependent) and improving overall precision of the assay. The lengths of the probe regions can be manipulated to achieve certain assay performance goals. For instance, cross-reaction with closely related targets can be minimized by adjusting the lengths of the various probe segments. As an example, in FIGS 6A, 6B, and 6C, probe regions 30, 32 of probe strands 1 and 3 can be relatively long and therefore form stable duplexes with target and even closely related non-target nucleic acids

that possess homologous sequences in these regions. Probe region 34 of probe strand 2 can be relatively short, and span a region that contains one or more mismatches 36 to non-target nucleic acids. This probe segment will form a stable duplex with perfectly matched target, but by virtue of its relative shortness will not form a stable duplex with mismatched targets.

[0060] The above examples show three way junctions between an arm and two target regions. Four way junctions can be created with three probes (although they may be formed as a single molecule) as shown in FIGS. 6E and 6F with separate arm regions (labelled A) and probe regions (P). Similar examples are shown in FIGS. 6H and 6G.

Example 4

[0061] A specific example of the general configuration shown in FIG. 6A is shown in FIG. 7. The probes are labelled 99 strand, 135 strand and 146 strand. As in Example 2, ribosomal RNA (rRNA) from *Neisseria gonorrhoeae* is the target nucleic acid. All oligomers were synthesized and AE-labeled as described in Example 1 above. Two basic designs were evaluated, both containing three probe strands that form two three-way nucleic acid junctions with the target strand. The only difference between the two designs is that one contains loop-out (L) bases at the junctions as indicated in FIG. 7. (More loop bases can be included in probes of this invention if desired; as can non-nucleotide bases. In addition, probes may be formed which create a non-fixed, or mobile, junction.)

[0062] A variety of linker-arm placements were evaluated, as indicated below. Furthermore, the exactly complementary target nucleic acid (*N. gonorrhoeae*) as well as a potentially cross-reacting target nucleic acid with 2 mismatches (*N. meningitidis*) were evaluated.

[0063] Hybridization characteristics of the different regions were evaluated using differential hydrolysis and T_m analyses as described in Example 1 with the following specific conditions: Structures 1-18 represented schematically in FIG. 8 were analyzed always using 0.6 pmol of the target strand, 0.1 pmol of AE-labeled probe strands, and 2 pmol of unlabeled probe strands; in samples 10-12 the target was *N. meningitidis*; in all the other samples, the target was *N. gonorrhoeae*; samples 1,2,4-6,10,11,13, 14,16 and 17 contained loop-out bases as shown in FIG. 7; the remaining samples did not contain loop-out bases. The resulting data are represented in tabular form in FIG. 8.

[0064] These data demonstrate that multiple arm regions can form in the presence of target, and only in the presence of target. Furthermore, multiple AE labels can be used in a single design, thus providing label amplification. Also, these structures can form with and without the loop-out bases shown in FIG. 7.

[0065] Selected structures from those shown in FIG. 8 were also evaluated for their ability to detect target nucleic acid (*N. gonorrhoeae*); cross-reaction with *N. meningitidis* was also tested. The general assay format was the same as that used in Example 3, with the following probe amounts: AE-labeled strands - 0.1 pmol; non-labeled probe strands - 2 pmol. The amounts of the target nucleic acids assayed and results are indicated below:

Structure (see Fig.8)	10-2 µg N.gon.	10-2µgN.men.	No target Control
1	29,820	817	726
4	28,564	1302	683
5	15,540	1892	1127
16	90,000	1309	1211

[0066] These data demonstrate that the designs shown here are useful in detecting small amounts of nucleic acid in a full assay format. Furthermore, significant label amplification is demonstrated in structure 16, which contains 3 AE-labeled strands instead of 1 (as in probe structures 1, 4 and 5). Cross-reaction with the very closely related *N. meningitidis* RNA is minimal for structure 16; the slight cross-reaction seen in the other structures could be reduced to minimal levels by slightly increasing the operating temperature of the assay, which was selected as the optimal for structure 16.

Non-target Junction Probes

[0067] Another configuration of branched nucleic acid probe used for the detection of target nucleic acids is represented schematically in FIGS. 9A-9F. This configuration is very similar to the one just described above in that the probe consists of three or more nucleic acid strands, e.g., shown as 40, 42, 44, which form two or more nucleic acid junctions, but in this case one or more of the junctions are formed with the target nucleic acid (such as 1 in FIG. 9A) and one or more of the junctions are not associated with the target (such as junction 2 in FIG. 9A) but are still formed only in the

presence of target. Virtually any combination of junctions is possible as long as the arm regions form a stable duplex only in the presence of target (the possibility of some of the arm regions forming a stable duplex even in the absence of target is discussed *infra*). Several examples of structures of this nature are represented schematically in FIGS. 9A-9F.

[0068] The guidelines for designing such a system are essentially the same as those for the configurations described above. The best combination of lengths and sequence of each region of each strand are typically determined experimentally by testing a variety of structures until the optimal combination is achieved. The design variables and the advantages of this configuration are essentially the same as those described above for the configuration represented by FIG. 6.

Example 5

[0069] A specific example of the general configuration shown in FIG. 9 is shown in FIG. 10. The target is a synthetic DNA 60mer (T) with a sequence corresponding to the major genetic translocation associated with chronic myelogenous leukemia (see Example 6 below). The probe consists of three strands, two of which form a 3-way junction with the target, and one of which forms a 3-way junction with the other two. This third strand contains only arm regions, and as such is a potential universal detection oligomer as discussed above. A single AE labeling site is detailed in this example, but AE can be placed in other regions as well.

[0070] To evaluate performance of this system, DH and T_m analyses were performed as described in Example 1 with the following specific conditions: target strand = 0.5 pmol; unlabeled probe strands = 2 pmol; AE-labeled probe strand = 0.1 pmol; differential hydrolysis was performed at 50°C. The results were as follows:

Half-life (min)			T _m (°C)	
Hybrid	Control	Ratio	Hybrid	Control
45.7	0.97	47.1	59.8	46.2

[0071] These data demonstrate that the two junctions of this structure form only in the presence of target (at the operating temperature) as evidenced by the lack of protection against AE hydrolysis of the AE-labeled strand. This is a unique situation in which the hybridization of a strand that does not even come into contact with the target strand is completely target dependent. This clearly demonstrates the concept of the universal detection oligomer discussed above. This also demonstrates the ability to form multiple junctions in response to target.

Chimeric Probes

[0072] In another configuration, a branched nucleic acid probe can be used to detect a chimeric nucleic acid target. A chimeric nucleic acid is a nucleic acid made up two or more segments that each originate from different sources or are otherwise unique (*e.g.*, the chimeric DNA only exists in a portion of a population of organisms) in some way. An example of such a chimeric target is the product of a genetic translocation as represented schematically in FIG. 11A. In this case, a segment of one chromosome is translocated onto another chromosome (and vice-versa in a reciprocal translocation), creating a chimeric DNA molecule (this may or may not result in a chimeric mRNA). This type of translocation can occur with multiple breakpoints (with one or both chromosomes), resulting in multiple chimeric DNA's. FIG. 11B represents a case in which 3 separate breakpoints on chromosome 2 reassociate with one breakpoint on chromosome 1.

[0073] Chimeric targets of this kind can be detected in a number of ways, examples of which are given in FIGS. 11C-11F. Method 1 (FIG. 11C) is a sandwich assay that requires a physical separation step. This method utilizes a capture probe specific for chromosome 1 (this capture probe is labeled with a specific capture agent, C, which allows it to be specifically removed from solution; for example, C may be biotin and the specific capture support may be avidin agarose), and 3 separate detection oligomers (each labeled with a reporter group) specific for the three different translocated regions of chromosome 2.

[0074] Method 2 (FIG. 11D) is a homogeneous assay that utilizes an AE-labeled probe specific for each translocation product (this is accomplished by designing the probes to "bridge" the breakpoint junction).

[0075] Method 3 (FIG. 11E and 11F) utilizes the method of this invention, in which a branched nucleic acid structure is formed around the breakpoint junction (other structures are possible, such as those shown in previous FIGS. in this application). Strand a is universal for all translocation products, and strands d, f and h are specific for the corresponding translocation products. In this particular example, strand a is the only strand that is AE-labeled. This system has several

advantages, including the following: it is homogeneous, not requiring the physical separation steps required in Method 1; it has a universal sequence for AE-protection, leading to uniform differential hydrolysis characteristics for each target; it has only 1 AE-labeled strand, minimizing complexity and cost and lowering backgrounds; it is less sensitive to mismatches (which can occur in the breakpoint junction region) than Method 2 (see Example 7). The guidelines for designing such a system are essentially the same as those for the configuration described in FIG. 1 above.

Example 6

[0076] A specific example of the general configuration shown in FIGS 11 is shown in FIGS. 12A-12C. The chimeric targets are synthetic DNA oligomers (80mers) homologous to 3 different genetic translocations between a constant *abl* region of chromosome 9 and various regions of chromosome 22. Two are the most common translocations associated with chronic myelogenous leukemia (CML) and one is associated with acute lymphocytic leukemia (ALL). Each chimeric target contains an identical *abl* region, whereas all regions from chromosome 22 are different. An 80mer corresponding to the normal *abl* gene (bridging the breakpoint 40 bases on either side) was also synthesized.

[0077] A single AE-labeled strand specific for the *abl* region was designed as shown in FIGS. 12A-12C. Three different strands were designed to contain a probe region specific for one of the translocated chromosome 22 regions as well as an arm region complementary to the arm region of the universal detection oligomer.

[0078] Performance of these 3 designs were first evaluated by measuring the differential hydrolysis rates and T_m 's for each using the protocol described in Example 1 (target - 0.5 pmol; AE-labeled probe strand - 0.1 pmol; unlabeled probe strand - 2 pmol). The results appear below:

Structure	Half-life (min.)			T_m (°C)
	Hybrid	Control	DH Ratio	
1	18.3	0.636	28.8	71.5
2	18.4	0.640	28.8	---
3	18.6	0.640	29.1	---

[0079] Next, the ability of the 3 probe mixes to detect the appropriate target sequences (and not react with the inappropriate target sequences) was evaluated. The assay format described in Example 4 was used (target - 20 fmol; AE-labeled probe strand - 0.1 pmol; unlabeled probe strand - 2 pmol). The results appear below (average of quadruplicate reactions):

Target	Probe mix 1	Probe mix 2	Probe mix 3	AE-labeled strand only
1	202,187	1,354	1,265	889
2	2,950	167,614	1,343	1,107
3	1,307	2,319	131,670	729
normal <i>abl</i>	1,491	1,248	1,094	886
no target	624	614	506	451

[0080] The probe mixes detect only the correct chimeric targets and do not cross-react significantly with either of the other two chimeric targets or the normal *abl* sequence, thus demonstrating the utility of this configuration for the detection of chimeric nucleic acid targets, and the use of a single AE-labeled probe strand for the detection of multiple targets.

Mismatch Probes

[0081] In another configuration, a branched nucleic acid probe is used to detect a variety of targets with related but non-identical sequences. Typically, DNA probe-based assays are designed to detect a specific target and to not cross-

react with closely related targets. In fact great effort has been expended to develop assays that will be sensitive to as little as one mismatch. However, there are cases when an assay needs to be relatively insensitive to mismatches. An example of such a case is the detection of viruses such as HIV, which display significant genomic variation.

5 Example 7

[0082] A specific example of the general configuration discussed above is shown in FIG. 13. The exact target strand is a synthetic DNA oligomer 78 bases in length with a sequence corresponding to a region of the gag gene in HIV-1. Other synthetic 78mers were also constructed to contain a variety of mismatches as shown in FIG. 13 (these sequences correspond to various HIV strains that have been isolated and sequenced). Two branched nucleic acid structures were evaluated, which have identical probe regions but different arm regions (see FIG. 14). The probe regions were designed to be very stable at the operating temperature, thus increasing the overall stability of the branched nucleic acid structure once formed with the target. The stability of each region, including the stability added by the arm regions (once hybridized), buffers against loss of stability in other regions caused by mismatches, thus decreasing the sensitivity of the overall structure to mismatches. All oligomers were synthesized and AE-labeled as described in Example 1 above.

[0083] Differential hydrolysis ratios and T_m 's of these designs were determined using the general protocols given in Example 1 above with the following specific conditions: target strand - 0.5 pmol; AE-labeled strand(s) - 0.1 pmol; unlabeled strand - 2 pmol; hybridizations and corresponding DH ratio analyses were performed at three different temperatures (60, 55 or 50°C; see below). The results are as follows:

25

30

35

40

45

50

55

Probe	AE-Strand	Target	NOM*	Temp†	Half-life(min)			%Hyb
					Hybrid	Control	DH Ratio	
1	1	1	0	60	4.3	0.56	7.7	---
	2				10.2	0.82	12.4	---
	1 & 2				7.4	0.75	9.8	---
	1	1	0	60	5.9	0.77	7.7	95
		2	3		7.7	0.77	10	59
		3	4		6.1	0.77	7.8	65
		4	6		10.0	0.77	13	6
	1	1	0	55	16.5	1.1	15	85
		2	3		13.9	1.1	12.6	79
		3	4		13.6	1.1	12.4	85
		4	6		9.8	1.1	8.9	57
	1	1	0	50	30.3	1.7	17.8	91
		2	3		41.6	1.7	24.5	76
		3	4		32.2	1.7	18.9	87
		4	6		17.8	1.7	10.5	82
								Tm(°C)
2	1	1	0	60	10.3	0.87	11.8	74
	2				9.8	1.5	6.5	71
	1 & 2				9.9	0.58	17	70
	2§	1	0	60	9.3	0.66	14.1	
		2	3		9.6	0.66	14.6	
		3	4		9.5	0.66	14.4	
		4	6		7.2	0.66	10.9	

* = Number of Mismatches.

† = DH Temperature (°C).

§ = Separate experiment

[0084] These results demonstrate that the branched nucleic acid probes can tolerate 3 and 4 mismatches with little or no effect on performance characteristics, and can tolerate 6 mismatches with only a small decrease in performance characteristics. Therefore branched nucleic acid probes can be used in assay formats that require relative insensitivity to mismatches. Furthermore, these data again demonstrate the ability to include multiple AE's per probe design (i.e., label amplification).

[0085] Structure 2 was further evaluated by detecting decreasing amounts of the perfectly matched target (target 1) in a full format assay as described in Example 4 (strands 1 and 2 AE labeled, 0.1 pmol each strand used; target concentrations given below). The results are as follows:

[Target] (fmol)	Signal (RLU)
30	840172

(continued)

[Target] (fmol)	Signal (RLU)
10	339581
3	114496
1	35022
0.3	11175
0.1	3755

[0086] These data demonstrate that the branched nucleic acid probe shown here is capable of detecting small quantities of target nucleic acid in a full format assay.

Detection of Branch Duplex

[0087] The target-dependent formation of a duplex between complementary arm regions of a branched nucleic acid probe can be detected using techniques other than the AE-label/differential hydrolysis technique discussed above. Furthermore, this differential duplex formation can give rise to a wide variety of biological or the chemical properties which are target-dependent. The two-strand branched nucleic acid probe described in FIG. 1 will be used as a model to discuss some examples of these properties, including alternate modes of detection. However, it will be readily recognized that these properties are applicable to any number of different branched nucleic acid probe configurations as long as the basic criterion that the arm regions in question form a stable duplex only in the presence of target is met.

Example 8: Restriction Endonuclease Cleavage

[0088] In one system (FIG. 15A), arm region duplex formation creates an active (double-stranded) restriction enzyme cleavage site (R) removed from the target strand. Cleavage at this site with a restriction endonuclease can be detected in a variety of ways. For example, one or both of the strands can be labeled with ^{32}P , and cleavage products can be detected using gel electrophoresis or other separation techniques. Alternatively, one or both of the strands can be labeled on one side of the cleavage site with a capture agent (such as biotin), and the other side of the cleavage site can be labeled with a reporter group (e.g., ^{32}P , AE). After cleavage, the strands are captured (with avidin agarose, for example), and reporter group associated with capture support indicates no cleavage, whereas reporter group associated with the supernatant indicates cleavage. Alternatively, a detection probe can be designed to react with the uncleaved strand but not the cleaved strand. This can be performed in a homogeneous or a separation assay (the homogeneous format is depicted in FIG. 15B). In one particular aspect of this system, the cleavage site is designed to be close to the base (i.e., the portion near the junction) of the arm region duplex. Upon cleavage with the restriction nuclease, the arm regions are almost entirely removed from the 3-way branched nucleic acid structure, thus reducing the stability of the overall structure. If the probe regions are designed to be stable only in the presence of intact arm duplex, once cleavage occurs the probe regions will melt off of the target. This will then allow uncleaved probe strands to hybridize with the target and start the process over again, thus increasing assay sensitivity by cycling multiple probes through a single target site.

Example 9: Selective degradation

[0089] In another system (FIG. 15C), one arm region is DNA and the other arm region (or portions thereof) is RNA. Formation of the arm duplex creates an active RNase H cleavage site. Cleavage with RNase H can be detected as described above for system 1. This system also has the potential for cycling as described above.

Example 10: Chemical Cleavage

[0090] In another system (FIG. 15D), a chemical cleavage agent (X, such as $\text{Fe} \cdot \text{EDTA}$ or $\text{Cu} \cdot \text{phenanthroline}$) specific for double-stranded nucleic acid is tethered to the arm region of one of the probe strands. When the arm region duplex is formed, cleavage of the nucleic acids in the immediate vicinity occurs (cleavage pattern is dependent on chemical cleaver and exact location and attachment chemistry). This cleavage can be detected as described above. This system also has the potential for cycling as described above.

[0091] Any other system that discriminates between single- and double-stranded nucleic acid is potentially applicable to the configuration generally described above, e.g., specific monoclonal antibodies for double-stranded nucleic

acid.

Example 11

[0092] A specific example of the system shown in FIG. 15A is shown in FIG. 16. This structure is the same as that shown in FIG. 2, except that the AE label is not included. A *Bst*EII restriction endonuclease site is engineered into the arm regions as shown. To analyze cutting of the arm regions \pm target nucleic acid, strand 2 of the probe was first labeled with ^{32}P using the standard kinasing protocol. Probe was then hybridized with target using the following conditions: Hybrid: 0.6 pmol ^{32}P -labeled strand 2; 15 pmol strand 1; 3 pmol target strand. Control: Same as hybrid, except no target. As a control of enzymatic activity, strand 2 was evaluated \pm an exactly complementary DNA target strand. These controls will be referred to as Linear-Hybrid and Linear-Control. The amounts used were the same as above (0.6 pmol ^{32}P -labeled strand 2; \pm 3 pmol target strand). These annealing reactions were incubated for 60 min at 60°C in 60 μl of 50mM Tris buffer, pH 7.9 (at 25°C), 500mM NaCl. Aliquots of each annealing reaction were then digested with *Bst*EII under the following conditions: 10 μl of each reaction above diluted to 10 μl with the final conditions of 50mM Tris buffer, pH 7.9 (at 25°C), 100mM NaCl, 10mM MgCl_2 , 1mM DTT. The samples were incubated with either 10, 5, 1 or 0.2 units of *Bst*EII (New England Biolabs) for 60 min at 60°C. Aliquots were then analyzed using standard polyacrylamide gel electrophoresis (20% gel, 500V, 15mA, 2.5 hours). A standard autoradiogram of the gel was then performed.

[0093] The results are shown in FIG. 17 and demonstrate target-dependent cleavage of the arm region duplex at 10 and 5 units of *Bst*EII. Furthermore, this restriction site can be any one that is desired since the sequence of the arm regions is independent of the target sequence. In this manner, use of a restriction enzyme will not be dependent on finding the correct recognition sequence in the target to be analyzed.

Example 12:

[0094] A specific example of the general configuration shown in FIG. 6E is shown in FIG. 21. The target strand is a synthetic 38mer oligomer; the probe strands form a 4-way junction with the target strand as shown. All oligomers were synthesized as described in Example 1 above. Hybridization characteristics of the structures shown in FIGS. 22A-22I (various schematic representations of the structure shown in FIG. 21) were evaluated using DH analysis protocols described in Example 1; all operations were performed at 50°C. The amounts of the different strands used were always the same (even if not all the strands were used) and were as follows: target strand - 1.5 pmol; strand 1 - 0.1 pmol; strand 2 - 6.5 pmol; strand 3 - 1.0 pmol. The following results were obtained:

Structure (Fig. Number)	Hydrolysis Half-life (min.)
22A	37.0
22B	0.54
22C	1.7
22D	0.72
22E	0.69
22F	0.60
22G	1.7
22H	42.7
22I	0.55

[0095] These data demonstrate that the AE is not protected from ester hydrolysis in the absence of target but is protected from ester hydrolysis in the presence of target (and the other probe strands). In this particular example, all four strands must be present to form a stable duplex between the arm regions of probe strands 1 and 2.

Target Independent Probe Amplification

[0096] In another configuration, some of the duplexes formed between complementary arm regions are formed independent of target (as long as at least one such duplex is formed only in the presence of target). Some examples of

this configuration are shown in FIGS. 19A-19B. One of the utilities of this configuration is label amplification, since AE or another label can be placed in multiple regions of a "network" of branched nucleic acid structures. Furthermore, when AE is the label, this configuration allows for a universal detection complex that could be used for any desired target site. This structure will become associated with the target molecule when the two (or more) probe regions hybridize to target, thus stabilizing the "anchor" junction (as depicted in FIGS. 19A and 19B). The target with this associated label amplification network will then typically have to be separated from unassociated network by some heterogeneous method (e.g., sandwich assay, hydroxyapatite capture of target nucleic acid). The number of junctions formed with target can be unlimited (at least up to 5, or even 10, and depending on the size of the probe, can be several thousands, so long as the hybridized probes do not precipitate from solution), as can the formation of a detection network which may associate with probe before or after hybridization to target.

[0097] In one case of the configuration discussed above, all the junctions could form in a target-independent manner. Some examples of this configuration are shown in FIGS. 20A-20C. This would allow for label amplification, using the branched nucleic acid structures to create networks, thereby allowing the incorporation of multiple labels per target site. This strategy can be used with a probe that forms a nucleic acid junction with the target strand (this junction is target-dependent in the sense that the full junction cannot form in the absence of target, but the duplex formed between associated arm regions is target-independent in that they form even in the absence of target), or a probe that does not form a nucleic acid junction with the target strand.

Therapeutic Probes

[0098] In addition to the detection and quantitation of nucleic acid targets, the branched nucleic acid probe configurations described herein can also be utilized in a variety of therapeutic applications. For example, the general configuration shown in FIG. 15, system 3, could be utilized by designing the probe regions to be specific for, e.g., an infectious organism, or specific cancer cells, and the arm regions to code for a biologically active molecule. The probes will hybridize with the target site, the template strand filled in by endogenous polymerases (this step might be unnecessary), producing an active coding region which will then generate (again via endogenous activities) a biologically active molecule, such as an inhibitor of an essential transcription or translation factor, a peptide or other small molecule that is toxic to the organism or cell, or an antigen that renders the cell susceptible to removal by the immune system.

[0099] Alternatively, the arm regions may form a double-stranded RNA region in a target-dependent manner, which in turn stimulates interferon activity. As another example, the junction formed with a target nucleic acid can be designed to form a site such that (at least) the target strand is cleaved by an endogenous resolvase enzyme. The probe will target a site where this cleavage would be lethal to the organism, or cell.

[0100] As another example, the duplex arm regions may create a recognition site for an endogenous nuclease that binds to this recognition site but cleaves at a distal site located on the target strand, with this cleavage leading to death of the organism, or cell. Alternatively, the arm region duplex will create a recognition site that competes for the binding of an essential endogenous regulation protein, or interferes with the assembly of an essential regulation complex in a sequence specific manner. Further, various combinations of probes could be designed to form stable branch points with an essential region of the target nucleic acid, thus blocking binding of sequence specific processing factors and thereby inhibiting replication.

[0101] Other embodiments are within the following claims.

Claims

1. A method for detecting the presence or amount of a target nucleic acid in a sample comprising the steps of:

contacting one or more nucleic acid molecules with said sample under a predetermined environmental condition to allow hybridization of said molecules if said target nucleic acid is present; wherein said one or more nucleic acid molecules together comprise at least two separate target regions which hybridize with said target nucleic acid under said predetermined environmental condition, and at least two arm regions, wherein said arm regions under said predetermined environmental condition do not hybridize with said target nucleic acid, or with each other in the absence of said target nucleic acid, but in the presence of said target nucleic acid do hybridize with each other; and

detecting any hybridization of said arm regions as an indication of the presence or amount of said target nucleic acid, wherein said detecting is not dependent upon interaction of two labels, one label being present on each arm region and said method does not involve detecting products resulting from primer extension of either of said at least two arm regions.

2. The method of claim 1 wherein said detecting step comprises contacting said one or more nucleic acid molecules

and said target nucleic acid with a resolvase and detecting cleavage of said one or more nucleic acid molecules by said resolvase.

- 5 **3.** The method of claim 1 wherein said detecting step comprises performing a DNA footprint analysis of said one or more nucleic acid molecules.
- 4.** The method of claim 1 wherein said detecting step comprises observing the mobility of said one or more nucleic acid molecules within a gel matrix.
- 10 **5.** The method of claim 1 wherein said detecting step comprises detecting the binding of an intercalator to said one or more nucleic acid molecules.
- 6.** The method of claim 1 wherein said detecting step comprises contacting said one or more nucleic acid molecules with S1 nuclease and detecting any cleavage of said one or more nucleic acid molecules by said nuclease.
- 15 **7.** The method of claim 1 wherein said detecting step comprises contacting said one or more nucleic acid molecules with a restriction endonuclease and detecting cleavage of said one or more nucleic acid molecules by said endonuclease.
- 20 **8.** The method of claim 1 wherein said detecting step comprises determining the thermal stability of said one or more nucleic acid molecules.
- 9.** The method of claim 1 wherein said one or more nucleic acid molecules comprises an intercalating molecule which is susceptible to chemical modification by an acid or a base when said molecule forms part of a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule and is not susceptible to such chemical modification when said molecule is present in the other of said single-stranded nucleic acid molecule or double-stranded nucleic acid molecule, and said detecting step comprises contacting said one or more nucleic acid molecules with said chemical and determining the amount of chemical modification of said molecule.
- 25 **10.** The method of claim 1 wherein at least one of said one or more nucleic acid molecules contains an acridinium ester.
- 11.** The method of claim 1 wherein at least one of said one or more nucleic acid molecules comprises a target region comprising between eight and one hundred contiguous bases complementary to a region of one thousand contiguous bases of said target nucleic acid.
- 30 **12.** The method of claim 1 wherein at least one of said one or more nucleic acid molecules comprises a target region comprising between eight and thirty contiguous bases complementary to a region of fifty contiguous bases of said target nucleic acid.
- 35 **13.** The method of claim 1 wherein said arm regions form a duplex in the absence of target nucleic acid with a melting temperature at least 4°C lower than the hybridization temperature in said predetermined environmental condition.
- 40 **14.** The method of claim 1 wherein said arm regions form a duplex in the absence of target nucleic acid with a melting temperature at least 7°C lower than said hybridization temperature in said predetermined environmental condition.
- 45 **15.** The method of claim 1 wherein said arm regions form a duplex in the absence of target nucleic acid with a melting temperature at least 10°C lower than said hybridization temperature in said predetermined environmental condition.
- 50 **16.** The method of claim 1 wherein said arm regions form a duplex in the presence of target nucleic acid with a melting temperature approximately 4°C higher than the hybridization temperature in said predetermined environmental condition.
- 55 **17.** The method of claim 1 wherein said arm regions form a duplex in the presence of target nucleic acid with a melting temperature approximately 7°C higher than the hybridization temperature in said predetermined environmental condition.

18. The method of claim 1 wherein said arm regions form a duplex in the presence of target nucleic acid with a melting temperature approximately 10°C higher than the hybridization temperature in said predetermined environmental condition.

19. The method of claim 1 wherein only one nucleic acid molecule is provided and said nucleic acid molecule comprises a loop region connecting at least said two arm regions.

20. The method of claim 1 wherein said one or more nucleic acid molecules consist of two nucleic acid molecules each comprising a target region and an arm region.

21. The method of claim 1 wherein said one or more nucleic acid molecules consist of three nucleic acid molecules each having at least one arm region and at least two of said nucleic acid molecules comprising a separate target region, wherein said three nucleic acid molecules hybridize with said target nucleic acid to form at least two separate duplexes between said arm regions.

22. The method of claim 1 wherein said one or more nucleic acid molecules consist of four nucleic acid molecules each comprising at least one arm region, and at least two said nucleic acid molecules comprising separate target regions, wherein said four nucleic acid molecules and said target nucleic acid hybridize to form at least three separate duplexes between said arm regions.

23. The method of claim 1 wherein said one or more nucleic acid molecules consist of five nucleic acid molecules each comprising at least one arm region, and at least two said nucleic acid molecules comprising separate target regions, wherein said five nucleic acid molecules and said target nucleic acid hybridize to form at least four separate duplexes between said arm regions.

24. The method of claim 1 wherein said target regions hybridize with said target nucleic acid, said arm regions hybridize together to form an arm, and a junction is formed at the base of said arm between said two separate target regions,

wherein said one or more nucleic acid molecules or said target nucleic acid may include nucleic acid adjacent said junction which does not form a duplex with said arm regions, said target regions, or said target nucleic acid, and loops out from said junction, or

wherein said target regions include along their length, or at the ends distant from said arm regions, nucleic acid which does not form a duplex with said target nucleic acid and either loops from a duplex formed between said target nucleic acid and said target region or extends as a single-stranded region from the end of said target region, or

wherein said arm regions comprise nucleic acid which does not form a duplex with said other arm region and forms a loop extending from said arm region or extends as a single-stranded molecule from the end of said arm region distant from said target region.

25. The method of claim 1 wherein said target regions hybridize with said target nucleic acid and said arm regions hybridize together to form an arm, wherein a junction is formed at the base of the arm between said two separate target regions, wherein one said arm region further comprises a single-stranded region at the end furthest from a said target region which fails to hybridize to said other arm region and is available for duplex formation with another nucleic acid molecule to form a second arm.

26. The method of claim 25 wherein both said arm regions comprise a said single-stranded region.

27. The method of claim 26 wherein said one or more nucleic acid molecules include a nucleic acid molecule able to form a duplex with said single-stranded regions to form a second or third arm and a second junction between the two or more said arms.

28. The method of claim 1 wherein said at least two arm regions form an arm when hybridized with said target nucleic acid, wherein said arm comprises a biologically or chemically active site.

29. The method of claim 28 wherein said site is a restriction endonuclease site.

30. The method of claim 28 wherein said site comprises a promoter for an RNA polymerase.

31. The method of claim 28 wherein said site comprises a DNA/RNA duplex susceptible to cleavage by RNase H.
32. The method of claim 28 wherein said site is a chemically active site comprising a chemical able to cleave adjacent duplex nucleic acid.
33. The method of claim 32 wherein said chemical comprises Fe.EDTA.
34. The method of claim 32 wherein said chemical comprises phenanthroline.
35. The method of claim 1 further comprising contacting said one or more nucleic acid molecules and said target nucleic acid with other nucleic acid molecules able to hybridize with said arm regions, or with single-stranded regions extending from said arm regions to form one or more other arms.
36. The method of claim 35 wherein said other nucleic acid molecules are able to hybridize among themselves to form a plurality of other arm regions.
37. The method of claim 28 wherein said active site can be cleaved by an agent to reduce the stability of said target regions and said target nucleic acid, and thereby allow one or more other nucleic acid molecules to hybridize with said target nucleic acid.
38. The method of claim 1, wherein at least one of said one or more nucleic acid molecules comprises phosphorothioate.
39. The method of claim 1, wherein one of said one or more nucleic acid molecules comprises a single-stranded nucleic acid region able to form a triple-stranded nucleic acid molecule with one said arm region or said target region hybridized to a complementary nucleic acid molecule.
40. A purified nucleic acid probe comprising one or more nucleic acid molecules together comprising at least two separate target regions which hybridize with a target nucleic acid under a predetermined environmental condition comprising a hybridization temperature, and at least two arm regions, wherein said arm regions, under said predetermined environmental condition, do not hybridize with said target nucleic acid, or with each other in the absence of said target nucleic acid, but in the presence of said target nucleic acid do hybridize with each other to form a detectable duplex which does not contain labels on each arm region interacting together to produce a detectable signal and which is not susceptible to detection by a method dependent upon primer extension of either of said at least two arm regions.
41. A purified nucleic acid probe comprising one or more nucleic acid molecules together comprising at least two separate target regions which hybridize with a target nucleic acid under a predetermined environmental condition comprising a hybridization temperature, and at least two arm regions, wherein said arm regions, under said predetermined environmental condition, do not hybridize with said target nucleic acid, or with each other in the absence of said target nucleic acid, but in the presence of said target nucleic acid do hybridize with each other to form a detectable duplex which does not contain labels on each arm region interacting together to produce a detectable signal,
wherein said probe contains means for detection of said duplex not dependent upon primer extension of either of said at least two arm regions.
42. A probe as claimed in claim 40 or claim 41 wherein said one or more nucleic acid molecules comprises an intercalating molecule which is susceptible to chemical modification by an acid or a base when said molecule forms part of a single-stranded nucleic acid molecule or a double-stranded nucleic acid molecule and is not susceptible to such chemical modification when said molecule is present in the other of said single-stranded nucleic acid molecule or double-stranded nucleic acid molecule.
43. A probe as claimed in claim 40 or claim 41 wherein at least one of said one or more nucleic acid molecules contains an acridinium ester.
44. A probe as claimed in any one of claim 40 to 43 wherein at least one of said one or more nucleic acid molecules comprises a target region comprising between eight and thirty complementary bases able to complex with a region

of fifty contiguous bases of said target nucleic acid.

45. A probe as claimed in any one of claims 40 to 43 wherein at least one of said one or more nucleic acid molecules comprises a target region comprising between eight and one hundred complementary bases able to complex with a region of one thousand contiguous bases of said target nucleic acid.
46. A probe as claimed in any one of claims 40 to 45 wherein said arm regions form a duplex in the absence of target nucleic acid with a melting temperature at least 4°C lower than the hybridization temperature in said predetermined environmental condition.
47. A probe as claimed in any one of claims 40 to 45 wherein said arm regions form a duplex in the absence of target nucleic acid with a melting temperature at least 7°C lower than said hybridization temperature in said predetermined environmental condition.
48. A probe as claimed in any one of claims 40 to 45 wherein said arm regions form a duplex in the absence of target nucleic acid with a melting temperature at least 10°C lower than said hybridization temperature in said predetermined environmental condition.
49. A probe as claimed in anyone of claims 40 to 48 wherein said arm regions form a duplex in the presence of target nucleic acid with a melting temperature approximately 4°C higher than the hybridization temperature in said predetermined environmental condition.
50. A probe as claimed in anyone of claims 40 to 48 wherein said arm regions form a duplex in the presence of target nucleic acid with a melting temperature approximately 7°C higher than the hybridization temperature in said predetermined environmental condition.
51. A probe as claimed in any one of claims 40 to 48 wherein said arm regions form a duplex in the presence of target nucleic acid with a melting temperature approximately 10°C higher than the hybridization temperature in said predetermined environmental condition.
52. A probe as claimed in any one of claims 40 to 51 wherein only one nucleic acid molecule is provided and said nucleic acid molecule comprises a loop region connecting at least two said arm regions.
53. A probe as claimed in any one of claim 40 to 51 wherein said one or more nucleic acid molecules consist of two nucleic acid molecules each comprising a target region and an arm region.
54. A probe as claimed in any one of claims 40 to 51 wherein said one or more nucleic acid molecules consist of three nucleic acid molecules each having at least one arm region and at least two of said nucleic acid molecules comprising a separate target region, wherein said three nucleic acid molecules hybridize with said target nucleic acid to form at least two separate hybridized pairs of arm regions.
55. A probe as claimed in any one of claim 40 to 51 wherein said one or more nucleic acid molecules consist of four nucleic acid molecules each comprising at least one arm region, and at least two said nucleic acid molecules comprising separate target regions, wherein said four nucleic acid molecules and said target nucleic acid hybridize to form at least three separate duplexes formed between said arm regions.
56. A probe as claimed in anyone of claims 40 to 51, wherein said one or more nucleic acid molecules consist of five nucleic acid molecules each comprising at least one arm region, and at least two said nucleic acid molecules comprising separate target regions, wherein said five nucleic acid molecules and said target nucleic acid hybridise to form at least four separate duplexes between said arm regions.
57. A probe as claimed in claim 40 or claim 41, wherein said target regions hybridize with said target nucleic acid, said arm regions hybridise together to form an arm, and a junction is formed at the base of the arm between said two separate target regions,

wherein said one or more nucleic acid molecules or said target nucleic acid may include nucleic acid adjacent said junction which does not form a duplex with said arm regions or said target regions or said target nucleic acid and loops out from said junction, or

wherein said target regions include along their length or at the ends distant from said arm regions nucleic acid which does not form a duplex with said target nucleic acid and therefore either loops from a duplex formed between said target nucleic acid and said target region or extends as a single-stranded region from the end of said target region, or

wherein said arm regions comprise nucleic acid which does not form a duplex with said other arm region and forms a loop extending from said arm region or extends as a single-stranded molecule from the end of said arm region distant from said target region.

58. A probe as claimed in claim 40 or claim 41 wherein said target regions hybridize with said target nucleic acid and said arm regions hybridize together to form an arm, wherein a junction is formed at the base of the arm between said two separate target regions, wherein one said arm region further comprises a single strand region at the end furthest from a said target region which fails to hybridize to said other arm region and is available for duplex formation with another nucleic acid molecule to form a second arm.

59. A probe as claimed in claim 58 wherein both said arm regions comprise a said single-stranded region.

60. A probe as claimed in claim 59 wherein said one or more nucleic acid molecules include a nucleic acid molecule able to form a duplex with said single-stranded regions to form a second or third arm and a second junction between said arms.

61. A probe as claimed in claim 40 or claim 41 wherein said at least two arm regions form an arm when hybridized with said target nucleic acid, wherein said arm comprises a biologically or chemically active site.

62. A probe as claimed in claim 61 wherein said site is a restriction endonuclease site.

63. A probe as claimed in claim 61 wherein said site comprises a promoter for an RNA polymerase.

64. A probe as claimed in claim 61 wherein said site comprises a DNA/RNA duplex susceptible to cleavage by RNase H.

65. A probe as claimed in claim 61 wherein said site is a chemically active site comprising a chemical able to cleave adjacent duplex nucleic acid.

66. A probe as claimed in claim 65 wherein said chemical comprises Fe.EDTA.

67. A probe as claimed in claim 65 wherein said chemical comprises phenanthroline.

68. A probe as claimed in claim 40 of claim 41 further comprising other nucleic acid molecules able to hybridize with said arm regions or with single-stranded regions extending from said arm regions to form one or more arms.

69. A probe as claimed in claim 68 wherein said other nucleic acid molecules are able to hybridize among themselves to form a plurality of arm regions.

70. A probe as claimed in claim 40 or claim 41, wherein at least one of said one or more nucleic acid molecules contains modified internucleotide linkages which are phosphorothioate linkages.

71. A probe as claimed in claim 40 or claim 41, wherein one of said one or more nucleic acid molecules comprises a single-stranded nucleic acid region able to form a triple-stranded nucleic acid molecule with one said arm region or said target region hybridized to a complementary nucleic acid molecule.

72. A probe as claimed in claim 40 or claim 41 wherein at least one of said one or more nucleic acid molecules contains a detectable label.

73. A probe as claimed in claim 40 or claim 41 wherein at least one of said one or more nucleic acid molecules consists of nucleotide bases having unmodified internucleotide linkages.

74. A kit for carrying out the detection method of claim 1, said kit comprising a probe as claimed in any one of claims 40 to 73, and means for detecting hybridization of said arm regions.

Patentansprüche

1. Verfahren zum Nachweis des Vorhandenseins oder der Menge einer Zielnukleinsäure in einer Probe, umfassend die folgenden Schritte:

Kontaktieren eines oder mehrerer Nukleinsäuremoleküle mit der Probe unter einem vorherbestimmten Umgebungszustand, um eine Hybridisierung der Moleküle zu erlauben, wenn die Zielnukleinsäure vorhanden ist; wobei das eine oder die mehreren Nukleinsäuremolekül(e) zusammen mindestens zwei separate Zielregionen umfaßt/umfassen, welche mit der Zielnukleinsäure unter der vorbestimmten Umgebungsbedingung hybridisieren, und mindestens zwei Armregionen, wobei die Armregionen unter der vorbestimmten Umgebungsbedingung nicht mit der Zielnukleinsäure, oder miteinander, in Abwesenheit der Zielnukleinsäure hybridisieren, aber in Gegenwart der Zielnukleinsäure miteinander hybridisieren; und

Nachweisen jeglicher Hybridisierung der Armregionen als eine Anzeige des Vorhandenseins oder der Menge der Zielnukleinsäure, wobei das Nachweisen nicht abhängig ist von der Wechselwirkung von zwei Markierungen, wobei eine Markierung auf jeder Armregion vorhanden ist, und das Verfahren nicht das Nachweisen von Produkten beinhaltet, welche aus einer Primer-Verlängerung von einer der mindestens zwei Armregionen resultieren.

2. Verfahren von Anspruch 1, wobei der Nachweisschritt das Kontaktieren des einen oder der mehreren Nukleinsäuremoleküle und der Zielnukleinsäure mit einer Resolvase und das Nachweisen von Spaltung des einen oder der mehreren Nukleinsäuremoleküle durch die Resolvase umfaßt.

3. Verfahren von Anspruch 1, wobei der Nachweisschritt das Durchführen einer DNA-Footprint-Analyse des einen oder der mehreren Nukleinsäuremoleküle umfaßt.

4. Verfahren von Anspruch 1, wobei der Nachweisschritt das Beobachten der Mobilität des einen oder der mehreren Nukleinsäuremoleküle innerhalb einer Gelmatrix umfaßt.

5. Verfahren von Anspruch 1, wobei der Nachweisschritt das Nachweisen der Bindung eines Interkalators an das eine oder die mehreren Nukleinsäuremoleküle umfaßt.

6. Verfahren von Anspruch 1, wobei der Nachweisschritt das Kontaktieren des einen oder der mehreren Nukleinsäuremoleküle mit S1-Nuklease und das Nachweisen jeglicher Spaltung des einen oder der mehreren Nukleinsäuremoleküle durch die Nuklease umfaßt.

7. Verfahren von Anspruch 1, wobei der Nachweisschritt das Kontaktieren des einen oder der mehreren Nukleinsäuremoleküle mit einer Restriktionsendonuklease und das Nachweisen von Spaltung des einen oder der mehreren Nukleinsäuremoleküle durch die Endonuklease umfaßt.

8. Verfahren von Anspruch 1, wobei der Nachweisschritt das Bestimmen der thermischen Stabilität des einen oder der mehreren Nukleinsäuremoleküle umfaßt.

9. Verfahren von Anspruch 1, wobei das eine oder die mehreren Nukleinsäuremolekül(e) ein interkalierendes Molekül umfassen, das anfällig für chemische Modifikation durch eine Säure oder eine Base ist, wenn das Molekül einen Teil eines einzelsträngigen Nukleinsäuremoleküls oder eines doppelsträngigen Nukleinsäuremoleküls bildet, und nicht anfällig für eine solche chemische Modifikation ist, wenn das Molekül in dem anderen von dem einzelsträngigen Nukleinsäuremolekül oder doppelsträngigen Nukleinsäuremolekül vorhanden ist, und der Nachweisschritt das Kontaktieren des einen oder der mehreren Nukleinsäuremoleküle mit der Chemikalie und das Bestimmen der Menge an chemischer Modifikation des Moleküls umfaßt.

10. Verfahren von Anspruch 1, wobei mindestens eines des einen oder der mehreren Nukleinsäuremoleküle einen Acridiniumester enthält.

11. Verfahren von Anspruch 1, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremoleküle(n) eine Zielregion umfaßt, umfassend zwischen acht und einhundert fortlaufende bzw. aneinandergrenzende Basen, komplementär zu einer Region von eintausend aneinandergrenzenden Basen der Zielnukleinsäure.

12. Verfahren von Anspruch 1, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremoleküle(n) eine Zielregion umfaßt, umfassend zwischen acht und dreißig aneinandergrenzende Basen, komplementär zu einer Region von fünfzig aneinandergrenzenden Basen der Zielnukleinsäure.
- 5 13. Verfahren von Anspruch 1, wobei die Armregionen einen Doppelstrang in Abwesenheit von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die mindestens 4°C niedriger ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.
- 10 14. Verfahren von Anspruch 1, wobei die Armregionen einen Doppelstrang in Abwesenheit von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die mindestens 7°C niedriger ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.
- 15 15. Verfahren von Anspruch 1, wobei die Armregionen einen Doppelstrang in Abwesenheit von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die mindestens 10°C niedriger ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.
- 20 16. Verfahren von Anspruch 1, wobei die Armregionen einen Doppelstrang in Gegenwart von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die ungefähr 4°C höher ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.
- 25 17. Verfahren von Anspruch 1, wobei die Armregionen einen Doppelstrang in Gegenwart von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die ungefähr 7°C höher ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.
- 30 18. Verfahren von Anspruch 1, wobei die Armregionen einen Doppelstrang in Gegenwart von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die ungefähr 10°C höher ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.
- 35 19. Verfahren von Anspruch 1, wobei nur ein Nukleinsäuremolekül vorgesehen wird und das Nukleinsäuremolekül eine Schleifen-Region umfaßt, welche die mindestens zwei Armregionen verbindet.
- 40 20. Verfahren von Anspruch 1, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus zwei Nukleinsäuremolekülen bestehen, die jeweils eine Zielregion und eine Armregion umfassen.
- 45 21. Verfahren von Anspruch 1, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus drei Nukleinsäuremolekülen bestehen, die jeweils mindestens eine Armregion aufweisen, und wobei mindestens zwei der Nukleinsäuremoleküle eine separate Zielregion umfassen, wobei die drei Nukleinsäuremoleküle mit der Zielnukleinsäure hybridisieren, um mindestens zwei separate Doppelstränge zwischen den Armregionen zu bilden.
- 50 22. Verfahren von Anspruch 1, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus vier Nukleinsäuremolekülen bestehen, die jeweils mindestens eine Armregion umfassen, und wobei mindestens zwei besagte Nukleinsäuremoleküle separate Zielregionen umfassen, wobei die vier Nukleinsäuremoleküle und die Zielnukleinsäure hybridisieren, um mindestens drei separate Doppelstränge zwischen den Armregionen zu bilden.
- 55 23. Verfahren von Anspruch 1, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus fünf Nukleinsäuremolekülen bestehen, die jeweils mindestens eine Armregion umfassen, und wobei mindestens zwei besagte Nukleinsäuremoleküle separate Zielregionen umfassen, wobei die fünf Nukleinsäuremoleküle und die Zielnukleinsäure hybridisieren, um mindestens vier separate Doppelstränge zwischen den Armregionen zu bilden.
24. Verfahren von Anspruch 1, wobei die Zielregionen mit der Zielnukleinsäure hybridisieren, die Armregionen unter Bildung eines Arms zusammenhybridisieren, und eine Verknüpfung bzw. ein Knotenpunkt an der Basis des Arms zwischen den zwei separaten Zielregionen gebildet wird,
wobei das eine oder die mehreren Nukleinsäuremoleküle oder die Zielnukleinsäure an die Verknüpfung angrenzende Nukleinsäure einschließen kann, welche keinen Doppelstrang mit den Armregionen, den Zielregionen oder der Zielnukleinsäure bildet und aus der Verknüpfung als Schleife herausragt, oder
wobei die Zielregionen entlang ihrer Länge, oder an den von den Armregionen entfernt gelegenen Enden,

Nukleinsäure einschließen, welche keinen Doppelstrang mit der Zielnukleinsäure bildet und entweder aus einem zwischen der Zielnukleinsäure und der Zielregion gebildeten Doppelstrang als Schleife herausragt oder als eine einzelsträngige Region von dem Ende der Zielregion herausragt, oder

- 5 wobei die Armregionen Nukleinsäure umfassen, welche keinen Doppelstrang mit der anderen Armregion bildet und eine Schleife bildet, die aus der Armregion herausragt, oder als ein einzelsträngiges Molekül von dem von der Zielregion entfernt gelegenen Ende der Armregion herausragt.
- 10 **25.** Verfahren von Anspruch 1, wobei die Zielregionen mit der Zielnukleinsäure hybridisieren und die Armregionen unter Bildung eines Arms zusammenhybridisieren, wobei eine Verknüpfung an der Basis des Arms zwischen den zwei separaten Zielregionen gebildet wird, wobei eine besagte Armregion ferner eine einzelsträngige Region an dem von einer besagten Zielregion entferntesten Ende umfaßt, welche darin versagt, an die andere Armregion zu hybridisieren, und für Doppelstrangbildung mit einem anderen Nukleinsäuremolekül verfügbar ist, um einen zweiten Arm zu bilden.
- 15 **26.** Verfahren von Anspruch 25, wobei die beiden Armregionen eine besagte einzelsträngige Region umfassen.
- 27.** Verfahren von Anspruch 26, wobei das eine oder die mehreren Nukleinsäuremolekül(e) ein Nukleinsäuremolekül einschließen, das in der Lage ist, einen Doppelstrang mit den einzelsträngigen Regionen zu bilden unter Bildung
20 eines zweiten oder dritten Arms und einer zweiten Verknüpfung zwischen den zwei oder mehreren besagten Armen.
- 28.** Verfahren von Anspruch 1, wobei die mindestens zwei Armregionen bei Hybridisierung mit der Zielnukleinsäure einen Arm bilden, wobei der Arm eine biologisch oder chemisch aktive Stelle umfaßt.
- 25 **29.** Verfahren von Anspruch 28, wobei die Stelle eine Restriktionsendonuklease-Stelle ist.
- 30.** Verfahren von Anspruch 28, wobei die Stelle einen Promoter für eine RNA-Polymerase umfaßt.
- 30 **31.** Verfahren von Anspruch 28, wobei die Stelle einen gegenüber Spaltung durch RNase H anfälligen DNA/RNA-Doppelstrang umfaßt.
- 32.** Verfahren von Anspruch 28, wobei die Stelle eine chemisch aktive Stelle ist, umfassend eine Chemikalie, die fähig ist, benachbarte Doppelstrang-Nukleinsäure zu spalten.
- 35 **33.** Verfahren von Anspruch 32, wobei die Chemikalie Fe.EDTA umfaßt.
- 34.** Verfahren von Anspruch 32, wobei die Chemikalie Phenanthrolin umfaßt.
- 40 **35.** Verfahren von Anspruch 1, ferner umfassend das Kontaktieren des einen oder der mehreren Nukleinsäuremoleküle und der Zielnukleinsäure mit anderen Nukleinsäuremolekülen, die fähig sind, mit den Armregionen zu hybridisieren, oder mit einzelsträngigen Regionen, die sich von den Armregionen erstrecken, um einen oder mehrere andere Anne zu bilden.
- 45 **36.** Verfahren von Anspruch 35, wobei die anderen Nukleinsäuremoleküle in der Lage sind, unter sich zu hybridisieren, um eine Vielzahl von anderen Armregionen zu bilden.
- 37.** Verfahren von Anspruch 28, wobei die aktive Stelle durch ein Mittel gespalten werden kann, um die Stabilität der Zielregionen und der Zielnukleinsäure zu vermindern und dadurch zu ermöglichen, daß ein oder mehrere andere
50 Nukleinsäuremoleküle mit der Zielnukleinsäure hybridisieren.
- 38.** Verfahren von Anspruch 1, wobei mindestens eines von den besagten einem oder mehreren Nukleinsäuremolekül(en) Phosphorthioat umfaßt.
- 55 **39.** Verfahren von Anspruch 1, wobei eines von den besagten einem oder mehreren Nukleinsäuremolekül(en) eine einzelsträngige Nukleinsäureregion umfaßt, die fähig ist, ein dreifachsträngiges Nukleinsäuremolekül mit einer Armregion oder der an ein komplementäres Nukleinsäuremolekül hybridisierten Zielregion zu bilden.

- 5 40. Gereinigte Nukleinsäuresonde, umfassend ein oder mehrere Nukleinsäuremolekül(e), die zusammen mindestens zwei separate Zielregionen umfassen, welche mit einer Zielnukleinsäure unter einer vorbestimmten Umgebungsbedingung, umfassend eine Hybridisierungstemperatur, hybridisieren, und mindestens zwei Armregionen, wobei die Armregionen unter der vorbestimmten Umgebungsbedingung nicht mit der Zielnukleinsäure, oder miteinander, in Abwesenheit der Zielnukleinsäure hybridisieren, aber in Gegenwart der Zielnukleinsäure miteinander hybridisieren, um einen nachweisbaren Doppelstrang zu bilden, der keine Markierungen auf jeder, miteinander unter Erzeugung eines nachweisbaren Signals interagierenden, Armregion enthält und der nicht einem Nachweis durch ein Verfahren zugänglich ist, das von Primer-Verlängerung von einer der mindestens zwei Armregionen abhängig ist.
- 10 41. Gereinigte Nukleinsäuresonde, umfassend ein oder mehrere Nukleinsäuremolekül(e), die zusammen mindestens zwei separate Zielregionen umfassen, welche mit einer Zielnukleinsäure unter einer vorbestimmten Umgebungsbedingung, umfassend eine Hybridisierungstemperatur, hybridisieren, und mindestens zwei Armregionen, wobei die Armregionen unter der vorbestimmten Umgebungsbedingung nicht mit der Zielnukleinsäure, oder miteinander, in Abwesenheit der Zielnukleinsäure hybridisieren, aber in Gegenwart der Zielnukleinsäure miteinander hybridisieren, um einen nachweisbaren Doppelstrang zu bilden, der keine Markierungen auf jeder, miteinander unter Erzeugung eines nachweisbaren Signals interagierenden, Armregion enthält,
- 15 wobei die Sonde ein Mittel zum Nachweis des Doppelstrangs enthält, das nicht von Primer-Verlängerung von einer der mindestens zwei Armregionen abhängig ist.
- 20 42. Sonde, wie beansprucht in Anspruch 40 oder 41, wobei das eine oder die mehreren Nukleinsäuremolekül(e) ein interkalierendes Molekül umfaßt/umfassen, das anfällig für chemische Modifikation durch eine Säure oder eine Base ist, wenn das Molekül einen Teil eines einzelsträngigen Nukleinsäuremoleküls oder eines doppelsträngigen Nukleinsäuremoleküls bildet, und nicht anfällig für eine solche chemische Modifikation ist, wenn das Molekül in dem anderen von dem einzelsträngigen Nukleinsäuremolekül oder doppelsträngigen Nukleinsäuremolekül vorhanden ist.
- 25 43. Sonde, wie beansprucht in Anspruch 40 oder 41, wobei mindestens eines des einen oder der mehreren Nukleinsäuremoleküle einen Acridiniumester enthält.
- 30 44. Sonde, wie beansprucht in mindestens einem von Anspruch 40 bis 43, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremoleküle(n) eine Zielregion umfaßt, umfassend zwischen acht und dreißig komplementäre Basen, die fähig sind, mit einer Region von fünfzig aneinandergrenzenden Basen der Zielnukleinsäure zu komplexieren.
- 35 45. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 43, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremoleküle(n) eine Zielregion umfaßt, umfassend zwischen acht und einhundert komplementäre Basen, die fähig sind, mit einer Region von eintausend aneinandergrenzenden Basen der Zielnukleinsäure zu komplexieren.
- 40 46. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 45, wobei die Armregionen einen Doppelstrang in Abwesenheit von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die mindestens 4°C niedriger ist als die Hybridisierungstemperatur bei dem vorherbestimmten Umgebungszustand.
- 45 47. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 45, wobei die Armregionen einen Doppelstrang in Abwesenheit von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die mindestens 7°C niedriger ist als die Hybridisierungstemperatur bei dem vorherbestimmten Umgebungszustand.
- 50 48. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 45, wobei die Armregionen einen Doppelstrang in Abwesenheit von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die mindestens 10°C niedriger ist als die Hybridisierungstemperatur bei dem vorherbestimmten Umgebungszustand.
- 55 49. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 48, wobei die Armregionen einen Doppelstrang in Gegenwart von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die ungefähr 4°C höher ist als die Hybridisierungstemperatur bei dem vorherbestimmten Umgebungszustand.
50. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 48, wobei die Armregionen einen Doppelstrang in Gegenwart von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die ungefähr 7°C höher ist als die

Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.

51. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 48, wobei die Armregionen einen Doppelstrang in Gegenwart von Zielnukleinsäure mit einer Schmelz-Temperatur bilden, die ungefähr 10°C höher ist als die Hybridisierungs-Temperatur bei dem vorherbestimmten Umgebungszustand.

52. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 51, wobei nur ein Nukleinsäuremolekül vorgesehen wird und das Nukleinsäuremolekül eine Schleifen-Region umfaßt, welche mindestens zwei besagte Armregionen verbindet.

53. Sonde, wie beansprucht in mindestens einem von Anspruch 40 bis 51, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus zwei Nukleinsäuremolekülen bestehen, die jeweils eine Zielregion und eine Armregion umfassen.

54. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 51, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus drei Nukleinsäuremolekülen bestehen, die jeweils mindestens eine Armregion aufweisen, und wobei mindestens zwei der Nukleinsäuremoleküle eine separate Zielregion umfassen, wobei die drei Nukleinsäuremoleküle mit der Zielnukleinsäure hybridisieren, um mindestens zwei separate hybridisierte Paare von Armregionen zu bilden.

55. Sonde, wie beansprucht in mindestens einem von Anspruch 40 bis 51, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus vier Nukleinsäuremolekülen bestehen, die jeweils mindestens eine Armregion umfassen, und wobei mindestens zwei besagte Nukleinsäuremoleküle separate Zielregionen umfassen, wobei die vier Nukleinsäuremoleküle und die Zielnukleinsäure hybridisieren, um mindestens drei separate Doppelstränge, gebildet zwischen den Armregionen, zu bilden.

56. Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 51, wobei das eine oder die mehreren Nukleinsäuremolekül(e) aus fünf Nukleinsäuremolekülen bestehen, die jeweils mindestens eine Armregion umfassen, und wobei mindestens zwei besagte Nukleinsäuremoleküle separate Zielregionen umfassen, wobei die fünf Nukleinsäuremoleküle und die Zielnukleinsäure hybridisieren, um mindestens vier separate Doppelstränge zwischen den Armregionen zu bilden.

57. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei die Zielregionen mit der Zielnukleinsäure hybridisieren, die Armregionen unter Bildung eines Arms zusammenhybridisieren, und eine Verknüpfung an der Basis des Arms zwischen den zwei separaten Zielregionen gebildet wird,

wobei das eine oder die mehreren Nukleinsäuremoleküle oder die Zielnukleinsäure an die Verknüpfung angrenzende Nukleinsäure einschließen kann/können, welche keinen Doppelstrang mit den Armregionen oder den Zielregionen oder der Zielnukleinsäure bildet und aus der Verknüpfung als Schleife herausragt, oder

wobei die Zielregionen entlang ihrer Länge, oder an den von den Armregionen entfernt gelegenen Enden, Nukleinsäure einschließen, welche keinen Doppelstrang bildet mit der Zielnukleinsäure und deshalb entweder aus einem zwischen der Zielnukleinsäure und der Zielregion gebildeten Doppelstrang als Schleife herausragt oder als eine einzelsträngige Region von dem Ende der Zielregion herausragt, oder

wobei die Armregionen Nukleinsäure umfassen, welche keinen Doppelstrang mit der anderen Armregion bildet und eine Schleife bildet, die aus der Armregion herausragt, oder als ein einzelsträngiges Molekül von dem von der Zielregion entfernt gelegenen Ende der Armregion herausragt.

58. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei die Zielregionen mit der Zielnukleinsäure hybridisieren und die Armregionen unter Bildung eines Arms zusammenhybridisieren, wobei eine Verknüpfung an der Basis des Arms zwischen den zwei separaten Zielregionen gebildet wird, wobei eine besagte Armregion ferner eine einzelsträngige Region an dem von einer besagten Zielregion entferntesten Ende umfaßt, welche darin versagt, an die andere Armregion zu hybridisieren, und zur Doppelstrang-Bildung mit einem anderen Nukleinsäuremolekül verfügbar ist, um einen zweiten Arm zu bilden.

59. Sonde, wie beansprucht in Anspruch 58, wobei die beiden Armregionen eine besagte einzelsträngige Region umfassen.

60. Sonde, wie beansprucht in Anspruch 59, wobei das eine oder die mehreren Nukleinsäuremolekül(e) ein Nukleinsäuremolekül einschließen, das in der Lage ist, einen Doppelstrang mit den einzelsträngigen Regionen unter Bildung eines zweiten oder dritten Arms und einer zweiten Verknüpfung zwischen den Armen zu bilden.
- 5 61. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei die mindestens zwei Armregionen bei Hybridisierung mit der Zielnukleinsäure einen Arm bilden, wobei der Arm eine biologisch oder chemisch aktive Stelle umfaßt.
- 10 62. Sonde, wie beansprucht in Anspruch 61, wobei die Stelle eine Restriktionsendonuklease-Stelle ist.
63. Sonde, wie beansprucht in Anspruch 61, wobei die Stelle einen Promoter für eine RNA-Polymerase umfaßt.
64. Sonde, wie beansprucht in Anspruch 61, wobei die Stelle einen gegenüber Spaltung durch RNase H anfälligen DNA/RNA-Doppelstrang umfaßt.
- 15 65. Sonde, wie beansprucht in Anspruch 61, wobei die Stelle eine chemisch aktive Stelle ist, umfassend eine Chemikalie, die fähig ist, benachbarte Doppelstrang-Nukleinsäure zu spalten.
66. Sonde, wie beansprucht in Anspruch 65, wobei die Chemikalie Fe.EDTA umfaßt.
- 20 67. Sonde, wie beansprucht in Anspruch 65, wobei die Chemikalie Phenanthrolin umfaßt.
68. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, ferner umfassend andere Nukleinsäuremoleküle, die fähig sind, mit den Armregionen oder mit einzelsträngigen Regionen, die sich von den Annregionen erstrecken, zu hybridisieren, um einen oder mehrere Arme zu bilden.
- 25 69. Sonde, wie beansprucht in Anspruch 68, wobei die anderen Nukleinsäuremoleküle in der Lage sind, unter sich zu hybridisieren, um eine Vielzahl von Armregionen zu bilden.
- 30 70. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremolekül(en) modifizierte Internukleotid-Bindungen enthält, bei denen es sich um Phosphorothioat-Bindungen handelt.
- 35 71. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei eines von den besagten einem oder mehreren Nukleinsäuremolekül(en) eine einzelsträngige Nukleinsäureregion umfaßt, die fähig ist, ein dreifachsträngiges Nukleinsäuremolekül mit einer besagten Armregion oder der an ein komplementäres Nukleinsäuremolekül hybridisierten Zielregion zu bilden.
- 40 72. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremolekül(en) eine nachweisbare Markierung enthält.
73. Sonde, wie beansprucht in Anspruch 40 oder Anspruch 41, wobei mindestens eines von dem einen oder den mehreren Nukleinsäuremolekül(en) aus Nukleotidbasen besteht, welche unmodifizierte Internukleotid-Bindungen aufweisen.
- 45 74. Kit zur Durchführung des Nachweisverfahrens von Anspruch 1, wobei das Kit eine Sonde, wie beansprucht in mindestens einem der Ansprüche 40 bis 73, und Mittel zum Nachweisen der Hybridisierung der Armregionen umfaßt.

Revendications

- 50 1. Méthode destinée à détecter la présence ou la quantité d'un acide nucléique cible dans un échantillon comprenant les étapes consistant :
- 55 à mettre en contact une ou plusieurs molécules d'acide nucléique avec ledit échantillon dans une condition de milieu prédéterminée afin de permettre l'hybridation desdites molécules si ledit acide nucléique cible est présent ; dans laquelle lesdites une ou plusieurs molécules d'acide nucléique ensemble comprennent au moins deux régions cibles séparées qui s'hybrident avec ledit acide nucléique cible dans ladite condition de milieu prédéterminée, et au moins deux régions de bras, dans laquelle lesdites régions de bras dans ladite condition

de milieu prédéterminée ne s'hybrident pas avec ledit acide nucléique cible, ou l'une avec l'autre en l'absence dudit acide nucléique cible, mais en présence dudit acide nucléique cible s'hybrident l'une avec l'autre ; et

à détecter toute hybridation desdites régions de bras comme une indication de la présence ou de la quantité dudit acide nucléique cible, dans laquelle ladite détection ne dépend pas de l'interaction de deux marqueurs, un marqueur étant présent sur chaque région de bras et ladite méthode ne fait pas intervenir de détection de produits résultant d'une élongation d'amorce de l'une ou l'autre desdites au moins deux régions de bras.

2. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend la mise en contact desdites une ou plusieurs molécules d'acide nucléique et dudit acide nucléique cible avec une résolvasse et la détection du clivage desdites une ou plusieurs molécules d'acide nucléique par ladite résolvasse.
3. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend la réalisation d'une analyse d'empreintes d'ADN (DNA footprint) desdites une ou plusieurs molécules d'acide nucléique.
4. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend l'observation de la mobilité desdites une ou plusieurs molécules d'acide nucléique dans une matrice de gel.
5. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend la détection de la liaison d'un agent intercalant auxdites une ou plusieurs molécules d'acide nucléique.
6. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend la mise en contact desdites une ou plusieurs molécules d'acide nucléique avec la nucléase S1 et la détection de tout clivage desdites une ou plusieurs molécules d'acide nucléique par ladite nucléase.
7. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend la mise en contact desdites une ou plusieurs molécules d'acide nucléique avec une endonucléase de restriction et la détection du clivage desdites une ou plusieurs molécules d'acide nucléique par ladite endonucléase.
8. Méthode selon la revendication 1 dans laquelle ladite étape de détection comprend la détermination de la stabilité thermique desdites une ou plusieurs molécules d'acide nucléique.
9. Méthode selon la revendication 1 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique comprennent une molécule intercalante qui peut subir une modification chimique par un acide ou par une base lorsque ladite molécule fait partie d'une molécule d'acide nucléique simple brin ou d'une molécule d'acide nucléique double brin et ne peut pas subir une telle modification chimique lorsque ladite molécule est présente dans l'autre de ladite molécule d'acide nucléique simple brin ou molécule d'acide nucléique double brin, et ladite étape de détection comprend la mise en contact desdites une ou plusieurs molécules d'acide nucléique avec ledit agent chimique et la détermination de la quantité de modification chimique de ladite molécule.
10. Méthode selon la revendication 1 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique contient un ester d'acridinium.
11. Méthode selon la revendication 1 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique comprend une région cible comprenant entre huit et cent bases contiguës complémentaires d'une région de mille bases contiguës dudit acide nucléique cible.
12. Méthode selon la revendication 1 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique comprend une région cible comprenant entre huit et trente bases contiguës complémentaires d'une région de cinquante bases contiguës dudit acide nucléique cible.
13. Méthode selon la revendication 1 dans laquelle lesdites régions de bras forment un duplex en l'absence d'acide nucléique cible avec une température de fusion d'au moins 4°C inférieure à la température d'hybridation dans ladite condition de milieu prédéterminée.
14. Méthode selon la revendication 1 dans laquelle lesdites régions de bras forment un duplex en l'absence d'acide nucléique cible avec une température de fusion d'au moins 7°C inférieure à ladite température d'hybridation dans ladite condition de milieu prédéterminée.

15. Méthode selon la revendication 1 dans laquelle lesdites régions de bras forment un duplex en l'absence d'acide nucléique cible avec une température de fusion d'au moins 10°C inférieure à ladite température d'hybridation dans ladite condition de milieu prédéterminée.
- 5 16. Méthode selon la revendication 1 dans laquelle lesdites régions de bras forment un duplex en présence d'acide nucléique cible avec une température de fusion approximativement de 4°C supérieure à la température d'hybridation dans ladite condition de milieu prédéterminée.
- 10 17. Méthode selon la revendication 1 dans laquelle lesdites régions de bras forment un duplex en présence d'acide nucléique cible avec une température de fusion approximativement de 7°C supérieure à la température d'hybridation dans ladite condition de milieu prédéterminée.
- 15 18. Méthode selon la revendication 1 dans laquelle lesdites régions de bras forment un duplex en présence d'acide nucléique cible avec une température de fusion approximativement de 10°C supérieure à la température d'hybridation dans ladite condition de milieu prédéterminée.
19. Méthode selon la revendication 1 dans laquelle seulement une molécule d'acide nucléique est fournie et ladite molécule d'acide nucléique comprend une région de boucle réunissant au moins lesdites deux régions de bras.
- 20 20. Méthode selon la revendication 1 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de deux molécules d'acide nucléique comprenant chacune une région cible et une région de bras.
- 25 21. Méthode selon la revendication 1 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de trois molécules d'acide nucléique ayant chacune au moins une région de bras et au moins deux desdites molécules d'acide nucléique comprenant une région cible séparée, dans laquelle lesdites trois molécules d'acide nucléique s'hybrident avec ledit acide nucléique cible pour former au moins deux duplex séparés entre lesdites régions de bras.
- 30 22. Méthode selon la revendication 1 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de quatre molécules d'acide nucléique comprenant chacune au moins une région de bras, et au moins deux desdites molécules d'acide nucléique comprenant des régions cibles séparées, dans laquelle lesdites quatre molécules d'acide nucléique et ledit acide nucléique cible s'hybrident pour former au moins trois duplex séparés entre lesdites régions de bras.
- 35 23. Méthode selon la revendication 1 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de cinq molécules d'acide nucléique comprenant chacune au moins une région de bras, et au moins deux desdites molécules d'acide nucléique comprenant des régions cibles séparées, dans laquelle lesdites cinq molécules d'acide nucléique et ledit acide nucléique s'hybrident pour former au moins quatre duplex séparés entre lesdites régions de bras.
- 40 24. Méthode selon la revendication 1 dans laquelle lesdites régions cibles s'hybrident avec ledit acide nucléique cible, lesdites régions de bras s'hybrident ensemble pour former un bras, et une jonction est formée à la base dudit bras entre lesdites deux régions cibles séparées,
45 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique ou ledit acide nucléique cible peuvent comprendre un acide nucléique adjacent à ladite jonction qui ne forme pas un duplex avec lesdites régions de bras, lesdites régions cibles, ou ledit acide nucléique cible, et forme une boucle à partir de ladite jonction, ou dans laquelle lesdites régions cibles comprennent sur leur longueur, ou aux extrémités éloignées desdites régions de bras, un acide nucléique qui ne forme pas un duplex avec ledit acide nucléique cible et soit forme
50 une boucle à partir d'un duplex formé entre ledit acide nucléique cible et ladite région cible soit s'étend sous forme d'une région simple brin à partir de l'extrémité de ladite région cible, ou dans laquelle lesdites régions de bras comprennent un acide nucléique qui ne forme pas un duplex avec ladite autre région de bras et forme une boucle s'étendant à partir de ladite région de bras ou s'étend sous forme d'une molécule simple brin à partir de l'extrémité de ladite région de bras éloignée de ladite région cible.
55 25. Méthode selon la revendication 1 dans laquelle lesdites régions cibles s'hybrident avec ledit acide nucléique cible et lesdites régions de bras s'hybrident ensemble pour former un bras, dans laquelle une jonction est formée à la base du bras entre lesdites deux régions cibles séparées, dans laquelle une dite région de bras comprend en outre

une région simple brin à l'extrémité la plus éloignée d'une dite région cible qui n'arrive pas à s'hybrider avec ladite autre région de bras et est disponible pour la formation d'un duplex avec une autre molécule d'acide nucléique pour former un deuxième bras.

- 5 **26.** Méthode selon la revendication 25 dans laquelle lesdites deux régions de bras comprennent une dite région simple brin.
- 10 **27.** Méthode selon la revendication 26 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique comprennent une molécule d'acide nucléique capable de former un duplex avec lesdites régions simple brin pour former un deuxième ou un troisième bras et une deuxième jonction entre les deux ou plus dits bras.
- 15 **28.** Méthode selon la revendication 1 dans laquelle lesdites au moins deux régions de bras forment un bras lorsqu'elles sont hybridées avec ledit acide nucléique cible, dans laquelle ledit bras comprend un site biologiquement ou chimiquement actif.
- 20 **29.** Méthode selon la revendication 28 dans laquelle ledit site est un site d'endonucléase de restriction.
- 25 **30.** Méthode selon la revendication 28 dans laquelle ledit site comprend un promoteur d'une ARN polymérase.
- 30 **31.** Méthode selon la revendication 28 dans laquelle ledit site comprend un duplex ADN/ARN susceptible d'être clivé par la RNase H.
- 35 **32.** Méthode selon la revendication 28 dans laquelle ledit site est un site chimiquement actif comprenant un agent chimique capable de cliver un duplex d'acide nucléique adjacent.
- 40 **33.** Méthode selon la revendication 32 dans laquelle ledit agent chimique comprend le Fe.EDTA.
- 45 **34.** Méthode selon la revendication 32 dans laquelle ledit agent chimique comprend la phénanthroline.
- 50 **35.** Méthode selon la revendication 1 comprenant en outre la mise en contact desdites une ou plusieurs molécules d'acide nucléique et dudit acide nucléique cible avec d'autres molécules d'acide nucléique capables de s'hybrider avec lesdites régions de bras, ou avec des régions simple brin s'étendant à partir desdites régions de bras pour former un ou plusieurs autres bras.
- 55 **36.** Méthode selon la revendication 35 dans laquelle lesdites autres molécules d'acide nucléique sont capables de s'hybrider entre elles pour former une pluralité d'autres régions de bras.
- 60 **37.** Méthode selon la revendication 28 dans laquelle ledit site actif peut être clivé par un agent afin de réduire la stabilité desdites régions cibles et dudit acide nucléique cible, et permettre ainsi à une ou plusieurs autres molécules d'acide nucléique de s'hybrider avec ledit acide nucléique cible.
- 65 **38.** Méthode selon la revendication 1, dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique comprend un phosphorothioate.
- 70 **39.** Méthode selon la revendication 1, dans laquelle l'une desdites une ou plusieurs molécules d'acide nucléique comprend une région d'acide nucléique simple brin capable de former une molécule d'acide nucléique triple brin avec une dite région de bras ou dite région cible hybridée avec une molécule d'acide nucléique complémentaire.
- 75 **40.** Sonde d'acide nucléique purifiée comprenant une ou plusieurs molécules d'acide nucléique ensemble comprenant au moins deux régions cibles séparées qui s'hybrident avec un acide nucléique cible dans une condition de milieu prédéterminée comprenant une température d'hybridation, et au moins deux régions de bras, dans laquelle lesdites régions de bras, dans ladite condition de milieu prédéterminée, ne s'hybrident pas avec ledit acide nucléique cible, ou l'une avec l'autre en l'absence dudit acide nucléique cible, mais en présence dudit acide nucléique cible s'hybrident l'une avec l'autre pour former un duplex détectable qui ne contient pas de marqueurs sur chaque région de bras interagissant ensemble pour produire un signal détectable et qui n'est pas susceptible d'être détecté par une méthode dépendant de l'élongation d'amorce de l'une ou l'autre desdites au moins deux régions de bras.
- 80 **41.** Sonde d'acide nucléique purifiée comprenant une ou plusieurs molécules d'acide nucléique ensemble comprenant

au moins deux régions cibles séparées qui s'hybrident avec un acide nucléique cible dans une condition de milieu prédéterminée comprenant une température d'hybridation, et au moins deux régions de bras, dans laquelle lesdites régions de bras, dans ladite condition de milieu prédéterminée, ne s'hybrident pas avec ledit acide nucléique cible, ou l'une avec l'autre en l'absence dudit acide nucléique cible, mais en présence dudit acide nucléique cible s'hybrident l'une avec l'autre pour former un duplex détectable qui ne contient pas de marqueurs sur chaque région de bras interagissant ensemble pour produire un signal détectable,

dans laquelle ladite sonde contient des moyens pour la détection dudit duplex indépendant de l'élongation d'amorce de l'une ou l'autre desdites au moins deux régions de bras.

42. Sonde telle que définie à la revendication 40 ou à la revendication 41 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique comprennent une molécule intercalante qui peut subir une modification chimique par un acide ou par une base lorsque ladite molécule fait partie d'une molécule d'acide nucléique simple brin ou d'une molécule d'acide nucléique double brin et ne peut pas subir une telle modification chimique lorsque ladite molécule est présente dans l'autre de ladite molécule d'acide nucléique simple brin ou molécule d'acide nucléique double brin.

43. Sonde telle que définie à la revendication 40 ou à la revendication 41 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique contient un ester d'acridinium.

44. Sonde telle que définie dans l'une quelconque des revendications 40 à 43 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique comprend une région cible comprenant entre huit et trente bases complémentaires capable de se complexer avec une région de cinquante bases contiguës dudit acide nucléique cible.

45. Sonde telle que définie dans l'une quelconque des revendications 40 à 43 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique comprend une région cible comprenant entre huit et cent bases complémentaires capable de se complexer avec une région de mille bases contiguës dudit acide nucléique cible.

46. Sonde telle que définie dans l'une quelconque des revendications 40 à 45 dans laquelle lesdites régions de bras forment un duplex en l'absence d'acide nucléique cible avec une température de fusion d'au moins 4°C inférieure à la température d'hybridation dans ladite condition de milieu prédéterminée.

47. Sonde telle que définie dans l'une quelconque des revendications 40 à 45 dans laquelle lesdites régions de bras forment un duplex en l'absence d'acide nucléique cible avec une température de fusion d'au moins 7°C inférieure à ladite température d'hybridation dans ladite condition de milieu prédéterminée.

48. Sonde telle que définie dans l'une quelconque des revendications 40 à 45 dans laquelle lesdites régions de bras forment un duplex en l'absence d'acide nucléique cible avec une température de fusion d'au moins 10°C inférieure à ladite température d'hybridation dans ladite condition de milieu prédéterminée.

49. Sonde telle que définie dans l'une quelconque des revendications 40 à 48 dans laquelle lesdites régions de bras forment un duplex en présence d'acide nucléique cible avec une température de fusion approximativement de 4°C supérieure à la température d'hybridation dans ladite condition de milieu prédéterminée.

50. Sonde telle que définie dans l'une quelconque des revendications 40 à 48 dans laquelle lesdites régions de bras forment un duplex en présence d'acide nucléique cible avec une température de fusion approximativement de 7°C supérieure à la température d'hybridation dans ladite condition de milieu prédéterminée.

51. Sonde telle que définie dans l'une quelconque des revendications 40 à 48 dans laquelle lesdites régions de bras forment un duplex en présence d'acide nucléique cible avec une température de fusion approximativement de 10°C supérieure à la température d'hybridation dans ladite condition de milieu prédéterminée.

52. Sonde telle que définie dans l'une quelconque des revendications 40 à 51 dans laquelle seulement une molécule d'acide nucléique est fournie et ladite molécule d'acide nucléique comprend une région de boucle réunissant au moins deux desdites régions de bras.

53. Sonde telle que définie dans l'une quelconque des revendications 40 à 51 dans laquelle lesdites une ou plusieurs

molécules d'acide nucléique sont constituées de deux molécules d'acide nucléique comprenant chacune une région cible et une région de bras.

54. Sonde telle que définie dans l'une quelconque des revendications 40 à 51 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de trois molécules d'acide nucléique ayant chacune au moins une région de bras et au moins deux desdites molécules d'acide nucléique comprenant une région cible séparée, dans laquelle lesdites trois molécules d'acide nucléique s'hybrident avec ledit acide nucléique cible pour former au moins deux paires hybridées séparées de régions de bras.

55. Sonde telle que définie dans l'une quelconque des revendications 40 à 51 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de quatre molécules d'acide nucléique comprenant chacune au moins une région de bras, et au moins deux desdites molécules d'acide nucléique comprenant des régions cibles séparées, dans laquelle lesdites quatre molécules d'acide nucléique et ledit acide nucléique cible s'hybrident pour former au moins trois duplex séparés formés entre lesdites régions de bras.

56. Sonde telle que définie dans l'une quelconque des revendications 40 à 51, dans laquelle lesdites une ou plusieurs molécules d'acide nucléique sont constituées de cinq molécules d'acide nucléique comprenant chacune au moins une région de bras, et au moins deux desdites molécules d'acide nucléique comprenant des régions cibles séparées, dans laquelle lesdites cinq molécules d'acide nucléique et ledit acide nucléique cible s'hybrident pour former au moins quatre duplex séparés entre lesdites régions de bras.

57. Sonde telle que définie à la revendication 40 ou à la revendication 41, dans laquelle lesdites régions cibles s'hybrident avec ledit acide nucléique cible, lesdites régions de bras s'hybrident ensemble pour former un bras, et une jonction est formée à la base du bras entre lesdites deux régions cibles séparées,

dans laquelle lesdites une ou plusieurs molécules d'acide nucléique ou ledit acide nucléique cible peuvent comprendre un acide nucléique adjacent à ladite jonction qui ne forme pas un duplex avec lesdites régions de bras ou lesdites régions cibles ou ledit acide nucléique cible et forme une boucle à partir de ladite jonction, ou dans laquelle lesdites régions cibles comprennent sur leur longueur ou aux extrémités éloignées desdites régions de bras, un acide nucléique qui ne forme pas un duplex avec ledit acide nucléique cible et donc soit forme une boucle à partir d'un duplex formé entre ledit acide nucléique cible et ladite région cible soit s'étend sous forme d'une région simple brin à partir de l'extrémité de ladite région cible, ou dans laquelle lesdites régions de bras comprennent un acide nucléique qui ne forme pas un duplex avec ladite autre région de bras et forme une boucle s'étendant à partir de ladite région de bras ou s'étend sous forme d'une molécule simple brin à partir de l'extrémité de ladite région de bras éloignée de ladite région cible.

58. Sonde telle que définie à la revendication 40 ou à la revendication 41 dans laquelle lesdites régions cibles s'hybrident avec ledit acide nucléique cible et lesdites régions de bras s'hybrident ensemble pour former un bras, dans laquelle une jonction est formée à la base du bras entre lesdites deux régions cibles séparées, dans laquelle une dite région de bras comprend en outre une région simple brin à l'extrémité la plus éloignée d'une dite région cible qui n'arrive pas à s'hybrider avec ladite autre région de bras et est disponible pour la formation d'un duplex avec une autre molécule d'acide nucléique pour former un deuxième bras.

59. Sonde telle que définie à la revendication 58 dans laquelle lesdites deux régions de bras comprennent une dite région simple brin.

60. Sonde telle que définie à la revendication 59 dans laquelle lesdites une ou plusieurs molécules d'acide nucléique comprennent une molécule d'acide nucléique capable de former un duplex avec lesdites régions simple brin pour former un deuxième ou un troisième bras et une deuxième jonction entre lesdits bras.

61. Sonde telle que définie à la revendication 40 ou à la revendication 41 dans laquelle lesdites au moins deux régions de bras forment un bras lorsqu'elles sont hybridées avec ledit acide nucléique cible, dans laquelle ledit bras comprend un site biologiquement ou chimiquement actif.

62. Sonde telle que définie à la revendication 61 dans laquelle ledit site est un site d'endonucléase de restriction.

63. Sonde telle que définie à la revendication 61 dans laquelle ledit site comprend un promoteur d'une ARN polymérase.

64. Sonde telle que définie à la revendication 61 dans laquelle ledit site comprend un duplex ADN/ARN susceptible d'être clivé par la RNase H.
- 5 65. Sonde telle que définie à la revendication 61 dans laquelle ledit site est un site chimiquement actif comprenant un agent chimique capable de cliver un duplex d'acide nucléique adjacent.
66. Sonde telle que définie à la revendication 65 dans laquelle ledit agent chimique comprend le Fe.EDTA.
- 10 67. Sonde telle que définie à la revendication 65 dans laquelle l'agent chimique comprend la phénanthroline.
68. Sonde telle que définie à la revendication 40 ou à la revendication 41 comprenant en outre d'autres molécules d'acide nucléique capables de s'hybrider avec lesdites régions de bras ou avec les régions simple brin s'étendant à partir desdites régions de bras pour former un ou plusieurs bras.
- 15 69. Sonde telle que définie à la revendication 68 dans laquelle lesdites autres molécules d'acide nucléique sont capables de s'hybrider entre elles pour former une pluralité de régions de bras.
- 20 70. Sonde telle que définie à la revendication 40 ou à la revendication 41, dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique contient des liaisons internucléotidiques modifiées qui sont des liaisons phosphorothioate.
- 25 71. Sonde telle que définie à la revendication 40 ou à la revendication 41, dans laquelle l'une desdites une ou plusieurs molécules d'acides nucléiques comprend une région d'acide nucléique simple brin capable de former une molécule d'acide nucléique triple brin avec l'une desdites régions de bras ou ladite région cible hybridée avec une molécule d'acide nucléique complémentaire.
72. Sonde telle que définie à la revendication 40 ou à la revendication 41 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique contient un marqueur détectable.
- 30 73. Sonde telle que définie à la revendication 40 ou à la revendication 41 dans laquelle au moins l'une desdites une ou plusieurs molécules d'acide nucléique est constituée de bases nucléotidiques ayant des liaisons internucléotidiques non modifiées.
- 35 74. Kit destiné à la mise en oeuvre de la méthode de détection de la revendication 1, ledit kit comprenant une sonde telle que définie dans l'une quelconque des revendications 40 à 73, et des moyens de détection de l'hybridation desdites régions de bras.

40

45

50

55




Figure 1A




Figure 1B




Figure 1C




Figure 1D




Figure 1E




Figure 1F








Figure 2A






Figure 3A




Figure 3B

—● indicates potential AE attachment site

Note: The 20 bases mentioned above are 5'-CGAAAGAUCAAGCUAAUACCG-3' in the target strand, and the probe is 5'-CGGTATTAGCTGATCTTTCG-3'. These bases were omitted to show the entire sequence of these probes.




Figure 4A




Figure 4B




Figure 5A

Hybrid 1




Figure 5B

Control 1




Figure 5E

Hybrid 2




Figure 5C

Control 2




Figure 5F

Hybrid 3




Figure 5D

Control 3




Figure 5G




Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 6E




Figure 6F




Figure 6G




Figure 6H




Figure 7

		<u>Half-Life (min)</u>		<u>DH Ratio</u>	<u>T_m (°C)</u>
		<u>Hybrid</u>	<u>Control</u>		
1.		18.19	0.53	34.3	66.5
2.		6.10	0.70	8.7	66.3
3.		22.32	0.55	40.6	66.1
4.		9.41	0.56	16.8	68.8
5.		7.67	0.72	10.7	67.8
6.		8.75	0.73	12.0	---
7.		10.02	0.56	17.9	67.9
8.		8.44	0.72	11.37	69.3
9.		8.83	0.75	11.8	64.5
10-12		3.31	0.56	5.9	58.4
		3.97	0.63	6.3	58.4
		5.42	0.57	9.5	58.7
		7.37	0.62	11.9	---
14.		6.76	0.60	11.3	---
15.		7.51	0.58	12.9	62.2
16.		5.79	0.73	7.9	62.0
17.		5.21	0.62	8.4	61.6
18.		6.36	0.64	9.9	61.4

† = Site of attachment. For samples 10-12, target = *N. men.*; for all other samples, target = *N. gon.* Amounts for all samples: target strand = 0.6 pmol; AE-labeled strand(s) = 0.1 pmol; unlabeled probe strands = 2 pmol.

Figure 8




Figure 9A




Figure 9B




Figure 9C




Figure 9D




Figure 9E




Figure 9F




Figure 10




Figure 11A






Figure 11B



Translocations





Figure 11E

Normal




Figure 11F




Figure 12A




Figure 12B




Figure 12C

Structure 2







Figure 13








Figure 15C




Figure 15D






Figure 16



LEGEND

1. Size markers
2. Branched-Hybrid; 10 units enzyme
3. Branched-Hybrid; 5 units enzyme
4. Branched-Hybrid; 1 unit enzyme
5. Branched-Hybrid; 0.2 units enzyme
6. Branched-Control; 10 units enzyme
7. Branched-Control; 5 units enzyme
8. Branched-Control; 1 unit enzyme
9. Branched-Control; 0.2 units enzyme
10. Linear-Hybrid; 10 units enzyme
11. Linear-Hybrid; 5 units enzyme
12. Linear-Hybrid; 1 unit enzyme
13. Linear-Hybrid; 0.2 units enzyme
14. Linear-Control; 10 units enzyme
15. Linear-Control; 5 units enzyme
16. Linear-Control; 1 unit enzyme
17. Linear-Control; 0.2 units enzyme

Figure 17






Figure 19B







FIGURE 21






Figure 22A




Figure 22E




Figure 22H




Figure 22B




Figure 22F




Figure 22I




Figure 22C




Figure 22G




Figure 22D